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ABSTRACT 
Human immunodeficiency virus-1 (HIV-1) enters the brain through blood brain barrier 
(BBB) early after the infection and leads to various neurological complications including HIV-
associated dementia (HAD). Introduction of combined Anti Retro Viral therapy (cART) has 
significantly reduced the incidence of HAD and increased the life expectancy of people 
infected with HIV. Increase in the life span of people resulted in the development of less 
severe forms of cognitive dysfunctions, including asymptomatic neurocognitive impairment 
(ANI) and Mild neurocognitive disorder (MND). These neurological deficits affect 
approximately 50% of HIV-1 infected people. The neurotoxicity of HIV-1 has been attributed 
to the virus itself or the viral proteins like HIV-1 Tat shed after the infection via several 
mechanisms including production of cytokines/chemokines and decreased expression of 
neuroplasticity genes. The present study was based on the central hypothesis that HIV-1 Tat 
and methamphetamine work synergistically in mediating pro-inflammatory cytokines and 
decreasing synaptic proteins. The level of cytokine expression mediated by HIV-1 Tat is 
determined. Furthermore, we examined the cellular mechanisms responsible for HIV-1 Tat 
mediated cytokine production, and the role of synaptic proteins in HIV-1 Tat and 
methamphetamine induced neurocognitive impairment.  
In the first chapter, we investigated the effect of HIV-1 Tat on pro-inflammatory 
cytokine expression in SVGA astrocytes. We measured levels of the IL-6, IL-8 and CCL5 in 
SVGA astrocytes after exposure with HIV-1 Tat. The results showed that HIV-1 Tat induced 
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expression of IL-6, IL-8 and CCL5 in a time-dependent manner. These results were also 
confirmed by detecting their intracellular expression in SVGA astrocytes using confocal 
microscopy. Next, we sought to explore the mechanism(s) by which HIV-1 Tat induces the 
cytokine response. The involvement of PI3K/Akt, p38 MAPK, JNK MAPK pathways and 
various transcription factors, including NF-κB and AP-1 were determined by using selective 
inhibitors and siRNAs.  
In the second chapter, we investigated combined the effect of HIV-1 Tat and 
methamphetamine on expression of IL-6 and its underlying signaling mechanism(s). 
In the third chapter, the effect of HIV-1 Tat and methamphetamine on neurocognition 
was determined in HIV-1 Tat transgenic mice. Y maze and Morris water maze were employed 
to determine neurocognition. We also determined the effect of Tat and methamphetamine on 
expression of synaptic proteins in various brain regions. Furthermore, the role of HIV-1 Tat 
and methamphetamine on neurotrophic factors and CaMKII were determined by western blot.  
In conclusion, we showed that HIV-1 viral protein Tat and methamphetamine were 
able to induce cytokine expression in astrocytes. The underlying mechanism(s) provides 
potential therapeutic target for neuroAIDS. 
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CHAPTER 1 
GENERAL INTRODUCTION 
1.1 Human immunodeficiency virus 
 The first historical evidence of Human Immunodeficiency Virus (HIV) was obtained 
from Luc Montagnier and team when they isolated it from the lymph node of a patient. They 
initially named it as lymphadenopathy-associated virus (Barre-Sinoussi, Chermann et al. 
1983). In another independent report, Robert Gallo had isolated the virus and named it as 
human T-cell lymphotropic retrovirus III (HTLV-III) (Broder and Gallo 1984). Furthermore, he 
reported for the first time that HTLV-III was responsible for pathogenesis of acquired 
immunodeficiency syndrome (AIDS). HIV belongs to the family of retroviridae. As the name 
implies, it contains reverse transcriptase (RT) enzyme that aids in the process of viral 
replication. Each virion contains a viral envelope that surrounds the capsid and matrix. The 
viral envelope is made from repeated trimers that are glycoproteins (Gelderblom, Ozel et al. 
1989). The capsid encloses two copies of single stranded RNA that are associated with 
integrase and RT. The RT enzyme helps in the conversion of RNA into DNA and integrase 
helps in the insertion of viral DNA into host DNA. HIV genome contains several genes that 
encode for various structural and functional proteins. These have diverse functions in HIV life 
cycle. 
Replication of HIV is associated with low fidelity, resulting in several mutations. HIV is 
found in two different strains, HIV-1 and HIV-2. HIV-1 bears close similarities to simian 
Immunodeficiency virus (SIV) isolated from chimpanzees whereas HIV-2 is related closely to 
SIV isolated from sooty mangabeys (Santiago, Range et al. 2005, Keele, Van Heuverswyn et 
al. 2006, Plantier, Leoz et al. 2009). Compared to HIV-2, HIV-1 is more pathogenic and 
predominant globally. Based on the similarities to SIV, HIV-1 is categorized into four different 
groups (M, N, O and P). Group M is the pathogenic form prevalent worldwide and is further 
divided into following sub-types/clades (A, B, C, D, F, G, H, J, K and circulating recombinant 
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forms). Clade B is common among people infected with HIV-1 in America, Europe and 
Australia. Clade C is dominant among people infected with HIV-1 in Sub-Saharan Africa, 
Brazil and India. 
1.2 HIV epidemiology 
 According to recent UNAIDS statistics published in 2015, more than 36.9 million 
people worldwide are living with HIV-1. Majority of this infected population live in Sub-Saharan 
Africa (25.8 million). The number of HIV infected people living in North America and Western 
and Central Europe together constitute 2.4 million. The number of newly infected people for 
the year 2014 alone includes 2 million people. Deaths due to AIDS related illnesses for the 
year 2014 alone include 1.2 million people. There are more than 5,600 new infections per day 
that occur worldwide because of HIV. Clade B represents 12% of HIV infections that are 
present globally. From a devastating disease, HIV infection has become a more manageable 
chronic condition after the advent of Highly Active Antiretroviral Therapy (HAART). HIV 
Figure 1: Adults and Children estimated to be living with HIV in 2014 (Source: UNAIDS) 
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presents as a huge economic burden on the society; estimated life time cost of treating a 
patient infected with HIV-1 is about $379,000. 
1.3 HIV infection and neuropathology 
 HIV crosses the blood brain barrier (BBB) soon after the infection (Davis, Hjelle et al. 
1992, An, Groves et al. 1999). Similar to the viruses belonging to the family of lentivirus, the 
entry of the HIV into the central nervous system (CNS) is well explained by Trojan horse 
phenomenon (Peluso, Haase et al. 1985, Haase 1986). After HIV infects a person, it harbors 
itself in the monocytes. As a part of immunological surveillance, the infected monocytes pass 
through the BBB, allowing the virus to be released inside the CNS. The released virus infects 
the different brain cells, including microglia, resident perivascular macrophages, endothelial 
cells and astrocytes (Wiley, Schrier et al. 1986, Cosenza, Zhao et al. 2002, Fischer-Smith, 
Croul et al. 2004, Liu, Liu et al. 2004, Eugenin, Clements et al. 2011). Other minor 
mechanisms that HIV utilizes to enter the brain include crossing of epithelial cells by 
transcytosis (Bomsel 1997) and utilizing cholesterol rich lipid rafts and heparin sulfate 
proteoglycans to infect brain microvascular endothelial cells (Argyris, Acheampong et al. 
2003). Infection of CNS by HIV results in the development of severe neurological 
complications, referred to as AIDS dementia complex (ADC). The numbers of HIV infected 
people with ADC were significantly higher (Portegies, Enting et al. 1993). However, after the 
onset of HAART, the incidence of people presenting with severe neurological complications 
have reduced significantly. Introduction of HAART has increased the life span of the people 
infected with HIV. This longevity has resulted in the development of milder forms of 
neurocognitive disorders. More than 50% of the people infected with HIV develop some form 
of neurocognitive impairment in their life time (Ozdener 2005). After the advent of HAART, 
neurological impairments associated with HIV were classified into three different groups by 
National institutes of health, including asymptomatic neurocognitive impairment (ANI), mild 
neurocognitive disorder (MND) and HIV associated dementia (HAD). The classification 
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referred to as Frascati criteria is widely accepted and brings all the impairments under one 
roof, referred to as HIV associated neurocognitive disorders (HAND). As the name implies, 
ANI does not affect the cognitive function whereas MND affects the cognitive function. Higher 
degree of neurocognitive impairment interferes with the individual’s ability to perform day to 
day activities (Antinori, Arendt et al. 2007). 
HIV infected people with neurological complications exhibit a distinct pattern of 
histopathological abnormalities. These anomalies include the presence of large 
multinucleated giant cells and other inflammatory cells in the CNS and damage to the brain 
white matter (Navia, Jordan et al. 1986, Budka, Wiley et al. 1991). Furthermore, the presence 
of activated astrocytes and microglia, elevated levels of β2-microglubulins, quinolinic acid and 
neopterin in cerebro spinal fluid (CSF) were used as diagnostic markers to characterize HIV-
encephalitis (Brew, Bhalla et al. 1989, Brew, Bhalla et al. 1990, Heyes, Brew et al. 1991). 
Postmortem brains of HIV infected people with neurological impairments resulting in HAD 
demonstrated different pathological features including, loss of neurons, reactive astrocytosis, 
BBB impairment and decrease in synaptic density (Everall, Luthert et al. 1993, Thompson, 
Churchill et al. 2004).  
Furthermore, apoptosis of neurons in the brain is a salient feature among the people 
infected with HIV (Adle-Biassette, Levy et al. 1995, Gelbard, James et al. 1995). However, 
neurons are not directly infected by the virus. The neuronal damage that is seen in HIV 
infected people with neurological complications can be mediated by direct effects and indirect 
effects of the virus. HIV, along with the released viral particles directly act on the neurons to 
induce pathological changes and eventually cause neurotoxicity. In addition to these direct 
effects, they can also act on the neighboring astrocytes and microglia to promote the release 
of various excitatory amino acids and other neurotoxic factors, including 
cytokines/chemokines, reactive oxygen species (ROS), nitric oxide synthase and quinolinic 
acid (Giulian, Vaca et al. 1990, Giulian, Wendt et al. 1993). The released excitatory amino 
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acids (EAA) act on the neurons to induce apoptosis by the process of exocytosis. This involves 
an increase in the intracellular levels of calcium, production of ROS and excessive stimulation 
of glutamate receptors (Bonfoco, Krainc et al. 1995). Even though there are insurmountable 
evidences indicating neurological impairments in HIV infected people, exact pathological 
mechanisms remain unknown.  
Considerable efforts are being made to understand the role of neuroimmune function 
of the brain during the HIV pathology. Alterations in the levels of various cytokines/chemokines 
are known to be associated with immune dysfunction (Hopkins and Rothwell 1995). Elevated 
levels of cytokines/chemokines are consistently present in HIV infected individual in the pre 
HAART and post HAART era (Epstein and Gendelman 1993, Roberts, Passmore et al. 2010). 
They often serve as biological markers for identification of neurological impairments in these 
individuals (Yuan, Qiao et al. 2013).  
1.4 Role of astrocytes in HAND 
Astrocytes comprise a majority of cells in the brain and occupy more than 50% of the 
brain volume. They play important roles in many brain functions, including the maintenance 
of homeostasis of the neurons, modulation of neuronal activity and regulation of synaptic 
plasticity (Halassa and Haydon 2010, Navarrete, Perea et al. 2012). They also represent an 
important reservoir for the production of various mediators of inflammation, particularly in 
response to HIV-1 (Minagar, Shapshak et al. 2002, Thompson, Churchill et al. 2004, Williams, 
Dhillon et al. 2009). Astrocytes are activated to a pathological state termed as reactive 
astrocytes in response to HIV-1 infection. Unlike microglia, astrocytes are restrictively infected 
with HIV due to the lack of CD4 receptors on their surface (Gorry, Ong et al. 2003). Post 
mortem studies have shown that astrocytes infected with HIV demonstrate some early HIV 
genes such as Negative factor (Nef), gag and rev that help in viral replication (Ranki, Nyberg 
et al. 1995). However, some studies have identified CD4 independent mechanisms for HIV to 
infect astrocytes. HIV utilizes mannose receptors expressed on the surface of astrocytes to 
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infect them (Liu, Liu et al. 2004). Furthermore, it has been shown that astrocytes can uptake 
the virus into the vesicle compartments and also infect naive CD4+ T cells (Clarke, Lake et 
al. 2006). These two pathways indicate that astrocytes can be a source for persistence of 
virus inside the brain and also infecting naïve cells. Astrocytes harbor latently infected virus 
that becomes productively infectious after triggered by various activating factors. In the 
presence of pro-inflammatory cytokines like IL-1β and TNF-α or co-culturing astrocytes with 
CD+ T cells, HIV recovers from dormant stage (Sabri, Tresoldi et al. 1999, Kore and Abraham 
2014). These studies indicate a potential role for the favorable stimuli to generate new viral 
copies from astrocytes. Several HIV proteins including, glycoprotein120 (gp120), HIV-1 Trans 
activator of transcription (HIV-1 Tat), Nef and Viral protein R (vpr) can act on various CNS 
cells to stimulate the production of various inflammatory stimuli like cytokines. Advent of 
modern technology has enabled us with sensitive techniques to measure the percentage of 
astrocytes that are infected with HIV. By employing laser capture microdissection, Churchill 
et al have shown that more than 18% of the astrocytes are infected with HIV in individuals 
with dementia (Churchill, Wesselingh et al. 2009). The amount of infection coupled with the 
fact that astrocytes are the most abundant cell type in the brain suggests that these cells play 
a crucial role in harboring significant amount of virus inside the CNS.  
1.5 HIV-1 Tat 
 Biochemical and mutation studies have helped to elucidate the structure of Tat. It is a 
basic protein of 86 to 101 amino acids in length depending upon the viral strain. Tat is divided 
into three different regions, including essential region (from 1-57 amino acids), auxiliary region 
(from 58-66 amino acids) and non-essential region (from 67-101 amino acids). Essential 
region is further divided into four functional domains (A, B, C and D). They include N-terminal 
domain (A), cysteine rich domain (B), Lys X Leu Gly Ile X Tyr domain (C) and basic domain 
(D). Mutations in cysteine rich region result in complete loss of transcriptional activity of Tat, 
indicating it is essential for Tat activity. Lysine amino acid of domain C is mainly responsible 
7 
 
for activity of Tat. Basic domain is required for localization of Tat into the cell and also essential 
for its transcriptional activity (Kuppuswamy, Subramanian et al. 1989). The basic domain 
along with the adjacent arginine domain specifically recognizes the hairpin loop structure rich 
in pyrimidines on transactivation RNA sequences (Weeks, Ampe et al. 1990). This results in 
the recruitment of positive transcription elongation factor b, resulting in the transcriptional 
elongation of viral promoter (Cann, Rosenblatt et al. 1985). As noted previously, Tat can be 
released from infected cells and can cross the BBB by various mechanisms. The free Tat 
protein inside the CNS causes neurotoxicity by various mechanisms. 
1.5.1 Effect of HIV-1 Tat on neuroinflammation 
Cytokines play a major role in inflammation and immune dysregulation and are 
implicated in several neurodegenerative disorders, including Alzheimer’s disease, 
Parkinson’s disease, multiple sclerosis and HIV-1 infection. Increased levels of various pro-
inflammatory cytokines/chemokines are seen in individuals infected with HIV-1. Levels of 
cytokines/chemokines are elevated in plasma and CSF of HIV-1 infected individuals. 
Production of cytokine interleukin-6 (IL-6) has been shown to promote viral replication of 
latently infected cells through the activation of various transcription factors via toll like receptor 
4 (Hoshino, Konishi et al. 2010) and also compromise proper function of BBB (Zidovetzki, 
Wang et al. 1998). HIV-1 Tat is one of the early viral proteins that is shown to promote the 
Figure 2: Structure of HIV-1 genome 
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release of cytokines/chemokines from various cells of CNS origin. Tat promotes the release 
of tumor necrosis factor-α (TNFα) and interleukin-10 (IL-10) from monocytes through the 
activation of toll like receptor 4 (TLR4) and various mitogen activated protein kinases (MAPKs) 
(Planes, Ben Haij et al. 2016). Tat also promotes the release of interleukin-6 (IL-6) and 
interleukin-8 (IL-8) from monocytes of HIV-1 infected and healthy individuals (Ben Haij, Planes 
et al. 2015). Tat induces the production of CCL2 to promote the activation of microglia and 
promote their migration (Eugenin, Dyer et al. 2005). Addition of HIV-1 Tat to primary microglia 
induces the down-regulation of fractalkine receptor and promotes up-regulation of various pro-
inflammatory cytokines, including interleukin-1β, (IL-1β), IL-6, IL-10 and TNF-α (Duan, Yao et 
al. 2014). Also, Tat induces the phosphorylation of leucine rich repeat kinase 2 and cyclic 
AMP phosphodiesterase to induce the production of different cytokines (Kiebala and 
Maggirwar 2011, Marker, Puccini et al. 2012). Tat promotes the release of various beta 
chemokines, including regulated upon activation, normal T cell expressed and secreted 
(CCL5), macrophage inflammatory protein-1alpha (CCL3), and macrophage inflammatory 
protein-1beta (CCL4) (Hahn, Vo et al. 2010). HIV-1 Tat stimulated the expression of astrocyte 
elevated gene-1 to promote the production of IL-1β and TNF-α cytokines from astrocytes 
(Vartak-Sharma, Gelman et al. 2014). Tat induced the diacetyl activity of Histone deacetylase 
6 (HDAC6) to promote the production of various chemokines, including CXCL 10 and CXCL8 
(Soo Youn, Ju et al. 2015). Tat interacts with various TLR’s on astrocytes to affect their 
expression and promote the production of TNF-α and IL-6 (El-Hage, Podhaizer et al. 2011). 
Induction of monocyte chemoattractant protein-1 (MCP-1/CCL-2) by HIV-1 Tat is inhibited by 
the use of specific siRNA or inhibitors against cyclin dependent kinase 9 (Khiati, Chaloin et al. 
2010). Tat also has been shown to promote the activation of vascular endothelial growth factor 
receptor and thereby induce up-regulation of various cytokines in brain endothelial cells to 
promote cytotoxicity (Khan, Di Cello et al. 2003). Tat has been shown to exhibit distinct effects 
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depending on the clade of virus, including, neuropathogenesis and neurotoxicity (Krishnan 
and Chatterjee 2015). Clade B has been shown to promote the production of 
cytokines/chemokines significantly compared to other clades, including clade A, clade C and 
clade D (Kennedy, Petrasca et al. 2014). Furthermore, Tat from clade B viral subtype is shown 
to be more toxic in brain microvascular endothelial cells in inducing inflammatory responses 
compared to Tat derived from HIV-1 circulating recombinant form, prominent viral subtype in 
Africa (Woollard, Bhargavan et al. 2014).  
Increased cytokine expression is associated with neurotoxicity by various 
mechanisms, including disruption of BBB and abnormal activation of NMDA receptors (Jara, 
Singh et al. 2007, Wardill, Mander et al. 2016). Targeting various pathways (CD45 or protein 
tyrosine phosphate) that are associated with the production of cytokines/chemokines is 
associated with decrease in the activation of microglia (Song, Jung et al. 2016). Furthermore, 
targeting Ankyrin-rich membrane spanning protein on microglia is associated with decrease 
in the expression of several pro-inflammatory cytokines (Singh, Wooten et al. 2015). Both 
these studies indicate the prominent role of inflammatory mediators as a drug target to reduce 
the severity of HAND. 
1.5.2 Effect of HIV-1 Tat on modulation of neurotransmitters 
Various neurotransmitters play vital roles inside the CNS, important being the 
transmission of impulses throughout the body, memory and synaptic plasticity. The important 
neurotransmitters include glutamate and dopamine. Excessive release of glutamate has been 
shown to cause neurotoxicity and eventually result in neuronal death (Rahn, Slusher et al. 
2012). Tat has been shown to affect the release of glutamate from astrocytes by down-
regulating the expression of excitatory amino acid transporter-2 (Zhou, Liu et al. 2004, 
Rumbaugh, Li et al. 2007). Tat also promotes the release of glutamate from microglia (Gupta, 
Knight et al. 2010). Furthermore, Tat activates N-methyl D-aspartate (NMDA) receptors and 
potentiates glutamate mediated neurotoxicity through the low density lipoprotein receptor 
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related protein and Rho associated protein kinase (Krogh, Lyddon et al. 2015). Activation of 
NMDA receptors by Tat evokes an abnormal increase in intracellular calcium levels leading 
to excitotoxicity (Bonavia, Bajetto et al. 2001). Brailoiu et al have performed comprehensive 
studies demonstrating excitatory effects of Tat. They have shown that nanomolar to 
micromolar concentrations of Tat has induces long lasting polarization and decrease 
membrane resistance in cortical neurons. Pre-treatment with various glutamate receptor 
inhibitors, including 6-cyano-7-nitroquinoxaline-2,3-dione and d-2-amino-5-phosphonovaleric 
acid have significantly reduced Tat mediated excitatory effects (Brailoiu, Brailoiu et al. 2008). 
Furthermore, increase in the release of glutamate associated with Tat has been shown to be 
primarily mediated by metabotropic glutamate receptor 1 (mGlu1), but not metabotropic 
glutamate receptor 5 (Musante, Summa et al. 2010). Consistent with the glutamate release 
findings, Tat has been shown to enhance the production of inositol 1,4,5-trisphosphate (IP3). 
Apart from actions of Tat on glutamate, Tat has been shown to affect various other 
neurotransmitters. These include the release of acetylcholine from cholinergic nerve terminals 
and norepinephrine from adrenergic nerve terminals (Longordo, Feligioni et al. 2006). Tat also 
potentiates the inhibitory effect by decreasing the release of inhibitory neurotransmitter 
gamma amino butyric acid (Xu and Fitting 2016). 
1.5.3 HIV-1 Tat and oxidative stress 
Reactive oxygen species (ROS) are implicated in wide array of diseases, including 
neurodegenerative diseases and cancers. Oxidative stress arises as an imbalance of various 
processes inside the cell to neutralize ROS. These reactive species result in the formation of 
peroxides, superoxides and free radicals that interact with different structures in the cell, 
including DNA and lipids to induce toxicity.  HIV-1 infection is associated with chronic oxidative 
stress, manifested by the reductions in the anti-oxidant defense systems and increased levels 
of various oxidative stress markers in the serum (Pace and Leaf 1995). These include 
decreased levels of superoxide dismutases, glutathiuone defense systems and elevated 
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levels of malonyldialdehyde and peroxides (Staal, Roederer et al. 1992, Ogunro, 
Ogungbamigbe et al. 2005). Induction of oxidative stress results in the damage to various 
cellular structures of the cell, including proteins, lipids and nucleic acids. 8-hydroxy-2' -
deoxyguanosine (8-OHdG) is one of the major lesion reported as a result of oxidative nucleic 
acid damage (Valavanidis, Vlachogianni et al. 2009). Prefrontal cortex autopsy of HIV infected 
individuals showed decreased levels of mitochondrial DNA and increased levels of 8-OHdG. 
HIV-1 Tat has been shown to induce oxidative stress in cell culture and animal models. Tat 
promoted apoptosis of rat hippocampal neurons by promoting the production of ROS 
(Kruman, Nath et al. 1998). Synaptosomes isolated from wild type mice treated with Tat 
showed increased production of ROS, oxidation of lipid and alteration in the membrane 
potential of mitochondria (Pocernich, Sultana et al. 2004). Tat disrupts the normal 
mitochondrial function and increases the levels of calcium inside the cytoplasm. This in turn 
increases the production of ROS from mitochondria and results in apoptosis of cells (Norman, 
Perry et al. 2008). Tat promotes the induction of nitric oxide from glial cells which triggers the 
release of excessive glutamate from astrocytes. The released glutamate acts on neurons to 
cause neurotoxicity. Furthermore Tat potentiates the effect of glutamate by activating 
spermine oxidase that promotes the production of hydrogen peroxide (Capone, Cervelli et al. 
2013). Tat induces ROS production to increase the expression of adhesion molecules 
(intercellular adhesion molecule-1 and vascular cell adhesion molecule-1) and thereby 
modulate the adhesion of monocytes (Song, Ryu et al. 2007). Furthermore, Tat can favor the 
entry of HIV into the CNS by mediating endothelial cytotoxicity through increased oxidative 
stress mediated inflammatory responses (Toborek, Lee et al. 2003). Tat also affects the 
enzymes such as glutathione, responsible for antioxidant defense systems to exacerbate 
oxidative stress mediated toxicity. Tat causes the up-regulation of anti-oxidant enzyme known 
as nuclear erythroid related factor 2 (Nrf2) that promotes the up-regulation of anti-oxidant 
defense systems. However, this increase in Nrf2 is not sufficient to counteract the oxidative 
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toxicity mediated by Tat and is required to promote HIV-1 long terminal repeat transactivation 
(Zhang, Li et al. 2009). Various other secondary markers of oxidative stress, including 
peroxidation of lipids have shown to be affected by Tat. 
1.6 HIV and drugs of abuse 
Use of recreational drugs for personal use is prominent worldwide, especially in the 
United States. According to the National Institute of Drug Abuse, more than 24 million people 
living in the United States have admitted to using at least one recreational drugs in one month 
for the year 2012 alone. This is 8.3% more than the number that is recorded in 2002. Drugs 
of abuse have been associated with HIV from its inception. Abuse of illicit drugs is higher 
among HIV seropositive individuals compared to HIV seronegative individuals (Garin, Velasco 
et al. 2015). Close to one-third of the population living with HIV abuse illicit drugs. Drug abuse 
ca increase the risky sexual behavior and poor judgement, which may lead a person to acquire 
HIV. Furthermore, the sharing and use of needles and syringes between injection drug users 
increases the chances of acquiring HIV. Drug abuse exacerbates the disease progression 
towards AIDS and also presents itself as a risk factor for the neurocognitive dysfunctions seen 
in HIV infected individuals (Nath, Hauser et al. 2002).  
1.7 Methamphetamine and HIV 
Methamphetamine is the second most commonly abused illicit drug word wide. In the 
USA alone, methamphetamine is abused in 10-15% of people infected with HIV (Cisneros 
and Ghorpade 2014). It poses a great risk for HIV-1 infection due to risky sexual behaviors, 
particularly among bisexual and gay men (Garofalo, Mustanski et al. 2007). It is mainly abused 
for its euphoric potential and stimulant properties on central and peripheral nervous systems. 
In small clinical doses, it is used to improve cognitive outcomes following brain injury. Also, it 
is used as a secondary drug of choice to treat patients with attention deficit hyperactivity 
disorder and refractory obesity (Kish 2008). In long term, it has severe effects on the central 
nervous system. It produces various behavioral problems, ranging from confusion, anxiety, 
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insomnia, delusions and hallucinations. Methamphetamine mainly affects the dopaminergic 
system and also GABAergic, serotonergic systems in different brain regions (Ricaurte, 
Schuster et al. 1980, Wilson, Kalasinsky et al. 1996). Methamphetamine abuse results in the 
neurotoxic effects on different regions of the brain, including frontal cortex, hippocampus, 
basal ganglia that are associated with memory, locomotion, cognition and executive functions 
(Belcher, O'Dell et al. 2005, Chang, Ernst et al. 2005, Berman, O'Neill et al. 2008). Consistent 
with these findings, methamphetamine use has been shown to impair learning and memory 
in human population and animal models (Scott, Woods et al. 2007, Siegel, Craytor et al. 2010, 
Kesby, Markou et al. 2015). The effects of methamphetamine on memory impairment are long 
lasting as measured by the decrease in prospective memory after 6 months of abstinence 
(Rendell, Mazur et al. 2009). Neurotoxicity mediated by methamphetamine is largely as a 
results of its action on the dopaminergic system (Riddle, Fleckenstein et al. 2006). 
Methamphetamine increases the concentration of dopamine in nerve terminals through 
various mechanisms, including decreased activity of dopamine transporter, decreased activity 
of tyrosine hydroxylase, reducing the activity of vesicular monoamine transporter and reduced 
degradation by monoamine oxidase (Silverstein, Shah et al. 2011, Coller and Hutchinson 
2012). 
Methamphetamine also binds to dopamine and trace amino acid 1 receptors to exhibit 
its neurotoxic potential (Ares-Santos, Granado et al. 2012).  It also acts on pre-synaptic 
terminals to facilitate the release of glutamate and thereby further enhancing the neurotoxic 
potential (Zhang, Jin et al. 2014). Ubiquitin proteasome system and autophagy are majorly 
responsible for degradation process and methamphetamine affects both the systems to cause 
neurodegeneration. This is evident by the increased presence of ubiquitin reactive neurons in 
the substantia nigra and mid brain (Quan, Ishikawa et al. 2005). Moreover, astrocytosis and 
dendritic pathology that are seen in HIV-1 infection are also associated with 
methamphetamine abuse (Kuczenski, Everall et al. 2007, Raineri, Gonzalez et al. 2012).   
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1.7.1 Methamphetamine and oxidative stress 
Methamphetamine has been shown for a long time to affect the redox balance in the 
body (Yamamoto and Bankson 2005). Oxidative stress induced by methamphetamine has 
been shown to play a major role in HIV pathogenesis. Release of nitric oxide by 
methamphetamine induces the release of dopamine that has been previously shown to be 
neurotoxic in in vitro and in vivo systems (Bowyer, Clausing et al. 1995). Use of specific nitric 
oxide inhibitors decrease the toxicity mediated by methamphetamine. Administration of 
methamphetamine to rats increased the expression of nitric oxide through the expression of 
dimethylarginine dimethylaminohydrolase 1, a major enzyme in nitric oxide synthesis pathway 
(Li, Wang et al. 2008). Furthermore, acute administration of methamphetamine resulted in the 
increased expression of various nitroproteins in the cell culture and rat striatum (Zhang, Chen 
et al. 2013). Increase in the expression levels of nitric oxide and glutamate further results in 
the activation of various molecules that result in the disruption of mitochondrial function 
(Sanchez-Alavez, Conti et al. 2013). These include disruption of complex II and complex II-III 
of mitochondrial electron transport chain. The effects are negated by the use of specific 
antagonists and scavengers against glutamate and peroxynitrite, respectively (Brown, 
Quinton et al. 2005). Furthermore, methamphetamine administration leads to increased 
expression of quinone, a secondary product of dopamine oxidation known to affect the 
function of mitochondrial enzymes (O'Shea, Urrutia et al. 2014). 
1.7.2 Methamphetamine and neuroinflammation 
Methamphetamine affects the normal functioning of the immune system. It affects the 
innate immune system function by stimulating the productions of various inflammatory stimuli. 
It shifts the balance to pro-inflammatory state by up-regulating the expression of pro-
inflammatory cytokines like TNF-α and IL-8 and decreasing the expression of anti-
inflammatory cytokines like CCL7 (Burns and Ciborowski 2016). Methamphetamine treatment 
increases the expression of trace amine-associated receptor 1 on T cells to induce the 
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activation of protein kinase C, a secondary messenger in immune activation and also 
stimulates the production of IL-2 (Sriram, Cenna et al. 2016). Methamphetamine induces the 
activation of various glial cells, including astrocytes and microglia. Activation of astrocytes and 
microglia is persistent for a long time even after methamphetamine withdrawal. Positron 
emission tomography of methamphetamine abusers showed elevated levels of (11)C](R)-(1-
[2-chlorophenyl]-N-methyl-N-[1-methylpropyl] -3-isoquinoline carboxamide, radiotracer for the 
detection of reactive microglia. The levels of radiotracer were increased in different brain 
regions (Sekine, Ouchi et al. 2008). Furthermore, methamphetamine affects the cell 
morphology of microglia making it to increase in its size (LaVoie, Card et al. 2004). It binds to 
sigma 1 receptor expressed on the surface of astrocytes to induce the expression of glial 
fibrillary acidic protein (GFAP), marker of astrocyte activation (Zhang, Lv et al. 2015). 
Hyperthermia, a characteristic feature of methamphetamine administration and neurotoxicity 
are also attenuated by the use of sigma receptor antagonist (Kaushal, Robson et al. 2014). 
Methamphetamine also affects the function of voltage gated potassium channels on microglia. 
It specifically up-regulates the expression of potassium channel Kv1.3 and promotes the 
outward current that results in cell death of microglia (Wang, Qian et al. 2014). Furthermore, 
methamphetamine mediated increase in the expression of IL-6 and TNF-α were decreased 
by the use of specific Kv1.3 antagonist. Methamphetamine showed increased expression of 
IL-6 and IL-8 cytokines in astrocytes through the activation of NF-κB pathway (Shah, 
Silverstein et al. 2012). Chronic methamphetamine treatment also reduces the expression 
levels of anti-inflammatory cytokines, including IL-2 and IFN-γ. Methamphetamine also 
increases the expression of cytotoxic inflammatory marker, cyclooxygenase-2 in striatum 
(Kita, Shimada et al. 2000). Methamphetamine decreases the expression of chemokines in 
dendritic cells, including MIP1α and MIP1β that can interact with HIV co-receptor (CCR5) to 
reduce the viral infection (Nair and Saiyed 2011).  
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1.8 Significance 
Significant amount of work has been undertaken to determine HIV pathogenesis. The 
present study was undertaken to determine the role of HIV-1 Tat and/or methamphetamine to 
alter the production of various cytokines/chemokines and expression of various synaptic 
proteins and neurotrophic factors. Production of neurotoxicity is a multifaceted approach and 
our study attempted to investigate the molecular mechanisms underlying the production of 
these cytokines/chemokines. We have also performed behavioral paradigm to determine the 
effects of HIV-1 Tat and/or methamphetamine on locomotion, anxiety and memory. The 
present study was based on the hypothesis that HIV-1 Tat and methamphetamine will interact 
with each other to increase the neurotoxicity, mediated by the production of various pro-
inflammatory cytokines/chemokines and also altering the expression of various synaptic 
proteins and neurotrophic factors. The long term goal of the current study is to develop a 
therapeutic strategy to block the production of various pro-inflammatory 
cytokines/chemokines or altered expression of various synaptic proteins and neurotrophic 
factors due to HIV-1 Tat and/or methamphetamine, which can decrease the progression 
towards HAND. The following specific aims were designed to elucidate our hypothesis: 
 To measure the role of HIV-1 Tat and methamphetamine on the expression of various 
pro-inflammatory cytokines/chemokines in SVG astrocytes and human fetal astrocytes 
 To investigate the molecular mechanisms underlying the expression of various pro-
inflammatory cytokines/chemokines induced by HIV-1 Tat and methamphetamine 
 To determine the effect of HIV-1 Tat and methamphetamine on locomotion, anxiety 
and memory by employing open field assay, light/dark box, Y maze and Morris water 
maze. 
 To assess the involvement of various synaptic proteins and neurotrophic factors in 
HIV-1 and methamphetamine induced behavior changes 
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The findings of the present study are of clinical importance as understanding the molecular 
mechanisms of increased neuroinflammation via cytokine/chemokine secretion and altered 
expression of synaptic proteins and neurotrophic factors, can lead to effective development 
of therapeutic strategies aimed at intervening the progression of HAND.  
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CHAPTER 2 
GENERAL MATERIALS AND METHODS 
2.1 Cell culture 
 All the experiments were performed using SVGA cells (Astroglial cells modified from 
simian virus 40 (SV40)-transformed human glial cells (SVG), originally developed by Dr. Major 
(Major, Miller et al. 1985). The cells were a generous gift from Dr. Avindra Nath. For the 
experiments involving primary human astrocytes, cells were gifted by Dr. Anuja Ghorpade. 
These cells were isolated from aborted fetus brain tissues. Both the cells were maintained 
Dulbecco’s modified eagle medium (DMEM) supplemented with 1% sodium bicarbonate, 1% 
Non-essential amino acids, 1% L-Glutamine, 10% heat inactivated fetal bovine serum and 50 
µg/ml of Gentamycin. The cells were maintained in an incubator at 370C and humidified air 
with 5% CO2. The cells were cultured in 150 cm2 flasks in 20 ml complete DMEM and 
passaged every alternate day. All the experiments were performed in either 6 well or 12 well 
plates with a seeding density of 0.7 million cells/well and 0.25 million cells/well, respectively. 
The cells were allowed to adhere overnight and the experiments were performed on the 
following day. 
2.2 Reagents and chemicals 
HIV-1 Tat expression plasmid was obtained from NIH aids research and reference 
reagent program (Catalog # 10453), initially developed by Dr. E Verdin, Gladstone institute, 
UCSF. Pharmacological inhibitors for NF-κB (BAY1170-82, SC-514), p38 (SB203580), JNK 
(SP600125), ERK1/2 (U0126), PI3K (LY294002) were purchased from Cayman chemicals 
(Ann Arbor, MI, USA). The recombinant HIV-1 Tat protein of 86 amino acids length (Catalog 
# 2222) was obtained from NIH aids research and reference reagent program. For all the 
experiments involving HIV-1 Tat protein, it was used at a concentration of 200 ng/ml. All the 
siRNA used in the experiments were pre-designed and validated. siRNA against p38 isoforms 
(α/β/γ/δ) (P/N AM51331; id 5213), p50 (P/N 4390420; id s9505), p65 (P/N AM4390824; id 
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s11914) and negative silencer control1 (scrambled) (# AM4611) were purchased from Ambion 
Inc (Carlsbad, CA, USA). siRNA against Akt1 (4390824; id s661). Akt2 (4390824; id s1215), 
akt3 (4392420; id s19429) isoforms, AP-1 (c-jun) (4392420; id s7660), C/EBPα (4392420; id 
s2890) and C/EBPγ (4392420; id s2902), JNK1 (4392420; id s28270) were purchased from 
Thermo Fisher Scientific (PA, USA). The primary antibodies for p65, p-c-jun, GAPDH, 
syanpsin1, synaptophysin, Shank2, PSD95, p-CaMKII and all the secondary antibodies 
against rabbit and goat were purchased from Cell Signaling (Danvers, MA. USA), primary 
antibodies for ARG3.1, CNTF and BDNF were purchased from abcam (Cambridge, MA, USA) 
and primary antibodies for p-p38, p-akt, p-JNK and LaminB were purchased from Santa cruz 
biotechnology (Dallas, TX, USA). Mounting medium containing 4',6-diamidino-2-phenylindole 
(DAPI) was obtained from Vector Laboratories (Burlingame, CA).  
2.3 Transfection 
 SVG astrocytes were transiently transfected with plasmid encoding HIV-1 Tat by using 
Lipofectamine 2000 (Life technologies, NY, USA) as previously described (Nookala, Shah et 
al. 2013). Briefly, astrocytes were plated in a 6 or 12 well plate and were allowed to adhere 
overnight. Next day, complete DMEM was removed and the cells were washed twice with 
PBS and serum free DMEM was added to the wells. A transfection mixture containing 
Lipofectamine and Optimem with or without 0.3 µg of HIV-1 Tat plasmid was added to the 
wells containing serum free medium. After 5 h, transfection mixture was replaced with 
complete DMEM. The cells were harvested at 1, 3, 6, 12, 24 and 48 hours post–transfection 
to determine the expression levels of various cytokines/chemokines at mRNA. Cell culture 
supernatants were also collected at various time points, including 6, 12, 24, 48, 72 and 96 
hours to determine the protein levels of various cytokines/chemokines. Experiments with 
pharmacological antagonists were performed by pretreating the cells 1 h prior to transfection 
with the plasmid coding for HIV-1 Tat. The doses of the antagonists were determined based 
on their IC50 values and dosage used by others. For experiments with small interfering RNA 
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(siRNA), 0.55 x 106 cells/well were seeded in a 6-well plate and were allowed to adhere 
overnight before transfecting with 50 nM siRNA. Briefly, complete media was removed from 
the plates and cells were washed twice with PBS before addition of serum free medium. The 
transfection mixture containing siRNA, Opti-MEM and Lipofectamine were added into the 
wells. After 24 h, the transfection mixture was replaced with complete media and the cells 
were allowed to grow for 10 h. After the mentioned time, cells were collected by trypsinization, 
counted and re-seeded at a density of 0.275 x 106 cells per well in a 12 well plate. The 
transfection with siRNA was performed for 24 h as opposed to 5 h (for Tat plasmid) in order 
to ensure the maximum knockdown of the target as reported previously. The following day, 
these cells were then transiently transfected with the HIV-1 Tat plasmid for 5 h and the cells 
were harvested at 6 h for determining the expression of mRNA and at 48 h for determining 
the protein expression. 
2.4 Quantitative real time RT-PCR 
 The cells were harvested at specific time points based on the experimental conditions 
and total RNA was extracted using RNeasy kit from Qiagen (Valencia, CA) as per the 
manufacturer’s recommendations. Briefly, cells were lyzed using 350 µl of RLT buffer, 
followed by precipitation of RNA using 350 µl of 70% ethanol. Then the cells were spun at 
10,000 rpm for 20 sec and the eluate was discarded. The columns were washed once with 
700 µl of RW1 buffer and twice with 500 µl of RPE buffer. 50 µl of RNAse free water was 
added into the column and the dissolved RNA was collected in the eluate in a pre-labeled 
tube. Concentration of RNA was measured and 150 ng was used to measure the mRNA 
expression levels of various cytokines/chemokines using real-time reverse transcription 
polymerase chain reaction (RT-PCR). Briefly, 150ng of RNA was reverse transcribed and 
amplified using the primers and PCR conditions as described in the following table (table 1). 
The expression levels of various genes were calculated by 2-ΔΔCt method using hypoxanthine 
phosphoribosyltransferase (HPRT) as an internal housekeeping gene.  
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2.5 Multiplex cytokine assay 
 The protein levels of cytokines/chemokines in the cell culture supernatants were 
measured using multiplex cytokine assay kit (Bio-Rad, CA, USA) as per the manufacturer’s 
protocol. Briefly, cell culture supernatants were collected from the plates at 6 h, 12 h, 24 h, 48 
h, 72 h, 96 h post-transfection followed by centrifugation twice at 1000g for 5 min. 50 µl of the 
samples and standards were mixed with magnetic beads and incubated on a shaker at room 
temperature for 30 min. The magnetic beads were washed and 25 µl of detection antibody 
was added to each well followed by incubation for 30 min. The samples were washed and 
incubated with 50 μl of streptavidin-PE conjugate for 10 min. Finally 125 μl of the assay buffer 
was added and the samples were analyzed using Biorad Bioplex HTS (Bio-Rad, CA, USA). 
The protein concentrations of cytokines/chemokines was determined with the Bio-plex 
manager 5 using 5-PL statistics.   
2.6 Western blotting 
 Cells were harvested at indicated time points to collect whole cell lysates and 
cytoplasmic and nuclear extracts. For whole cell extract preparation and animal tissues, RIPA 
buffer was used to lyse the cells and tissues, followed by homogenization and spinning at 
10,000 rpm for 10 min to remove the cell debris. Nuclear and cytoplasm fractions were 
separated at indicated time points using the following protocol. Briefly, the cells were 
trypsinized and centrifuged at 10,000 rpm for 5min. The cell pellet was resuspended in 300 µl 
of cytoplasmic buffer, followed by incubation on ice for 10 min and wash with 500µl of ice cold 
PBS. Then 200 µl of nuclear buffer was added to the remaining pellet and was incubated on 
ice for 15 min. The suspension was vortexed intermittently and was centrifuged at 14,000 rpm 
for 10 min to obtain the nuclear portion. The concentrations of the proteins were determined 
from the standard curve using BCA kit (Pierce biotechnology, IL, USA).  20 µg of protein was 
loaded into the wells of 12% polyacrylamide gel. Electrophoresis was performed at 80V for 3 
h followed by transfer onto a PVDF membrane for 90 min at 350 mA. The membrane was 
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blocked in 5% Nonfat Dry Milk for 1 h. The membranes were incubated in primary antibody 
overnight at 40C. The details and dilutions of antibodies are described in the table 3. The 
membranes were washed with PBST and incubated in the appropriate HRP conjugated 
secondary antibody for 90 min. The membranes were washed with PBST and the proteins 
were visualized by using BM Chemiluminescence Western Blotting Substrate (POD) (Roche 
Applied Sciences, Indianapolis, IN). The bands were analyzed and quantified by Flourchem 
HD2 software (Alpha Innotech, San Leandro, CA). GAPDH and LaminB were used as internal 
loading controls for cytoplasmic and nuclear protein, respectively, to normalize the expression 
of proteins of interest. 
2.7 Immunocytochemistry 
SVGA cells were seeded at a density of 0.6 X 106 cells/well in a 6-well plate on glass 
cover slips in each well. The cells were allowed to adhere overnight, followed by transfection 
with the HIV-1 Tat plasmid for 12 h on the following day. 6 h prior to the termination, 10 µl of 
1 mg/ml Golgi-stopTM (BD Biosciences, CA, USA) solution was added into each well in order 
to prevent the release of cytokines/chemokines into the supernatant. After specified time, 
complete DMEM was removed from the wells and the cells were fixed by the addition of 1:1 
ice cold methanol and acetone solution and kept at -200C for 20 min. The wells were air dried 
and the cover slips were incubated for 10 min in PBST (0.1% Triton-X in PBS). This was 
followed by 3 washes with PBS and blocking with 1% bovine serum albumin in PBST for 30 
min. The cells were washed and further incubated for overnight with the mixture of antibodies 
for mouse anti-glial fibrillary acidic protein (anti-GFAP) (1:1000) and rabbit anti-IL-6 (1:500) or 
anti-IL-8 (1:500) or anti-CCL5 (1:500). On the following day, cells were washed thrice with 
PBST and the secondary antibodies (Alexafluor 555 labeled Anti-mouse IgG and Alexafluor 
488 labeled anti-rabbit IgG) were added at a dilution of 1:1000 and the cover slips were 
incubated in dark for 1 h. The cover slips were gently taken out from the wells and washed 
with PBST before being transferred onto a glass slide containing the mounting medium with 
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4',6-diamidino-2-phenylindole (DAPI) (Vector Laboratories, Burlingame, CA). The images 
were obtained using inverted confocal microscope, Leica TCS SP5 II (Leica Microsystems, 
Wetzler, Germany). The intensity of cytokines/chemokines was calculated using imageJ 
software and GFAP was used as a house keeping gene to normalize the intensity values. 
2.8 Animals 
 Doxycycline inducible HIV-1 Tat transgenic mice obtained from Dr. Kurt Hauser at 
Virginia Commonwealth University were used for the experiments. The expression of Tat in 
this transgenic line was under the control of glial fibrillary acidic promoter (GFAP) promoter 
and thereby, expression was restricted to astrocytes. Both Tat positive and Tat negative mice 
expressed reverse tetracycline transactivator gene whereas only Tat positive mice expressed 
Tat gene. All the mice were housed and bred at UMKC Laboratory Animal Research Core. 
Mice were genotyped to confirm the presence of Tat transgene. Eight week old HIV-1 Tat (+) 
and HIV-1 Tat (-) mice were administered doxycycline (6 mg/kg) for a duration of 16 weeks 
before they were subjected to behavior testing. All the behavioral tests were performed 
between 8:00 AM to 5:00 PM. All the procedures were approved and conducted in accordance 
with UMKC Institutional Animal Care and Use Committee. 
2.9 Drug regimen 
To simulate chronic methamphetamine use in human abusers, we employed 
escalating dosing regimen in mice. Methamphetamine (Sigma, St. Louis, USA) was dissolved 
in PBS and was administered intraperitoneally twice a day. The dose of methamphetamine 
was escalated stepwise from 0.1 mg/kg to 6 mg/kg over 7 day duration.  After the escalation 
period, a maintenance dose of 6 mg/kg methamphetamine was given b.i.d for the remaining 
duration of experiment. Control mice received similar amount of PBS intraperitoneally.  
2.10 Open field assay 
Open field assay is used to determine the locomotor activity and level of anxiety. The 
chamber consists of a 40cm x 40 cm and covered on four sides with a black opaque plexi 
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glass. Infra-red photo beam arrays were placed 2 inches above the base of the testing floor 
on opposite sides. These beams are used to record the rearing activity of the mice. The 
procedure for performing the assay is as follows. The mice were bought in to the testing room 
and were allowed to acclimatize for 1 h. Mouse was placed into the chamber into one of the 
corners at random. Activity of the mice was recorded by means of an overhead camera over 
a duration of 6 min. The chamber was cleaned with 70% ethanol before testing the subsequent 
mouse to prevent odor trail. Total distance traveled by the mice over entire trial duration was 
calculated and serves as an indicator of locomotor activity. Furthermore, the amount of time 
spent and distance traveled by the mice at the center and the periphery were calculated. 
These two parameters served as an indicator of anxiety.  
2.11 Light/dark box assay 
Light/dark box is an important tool to measure the level of anxiety. The box consists of 
two chambers, a light chamber and a dark chamber. Two chambers are separated by a black 
opaque plexi glass with an opening in the center. Infra-red photo beam arrays were placed 2 
inches above the base of the testing floor on opposite sides. These beams are used to record 
the rearing activity of the mice. The procedure for performing the assay is as follows. Animal 
was placed in the dark chamber and the test was started. The activity of the animal was 
monitored over a duration of 10 min by means of an overhead camera. The chamber was 
cleaned with 70% ethanol before testing the subsequent mouse to prevent odor trail. Time 
spent and distance traveled by the mice in the light compartment were calculated. These two 
parameters serve as measures of anxiety like phenomenon in mice. 
2.12 Y Maze 
 Y maze measures spatial working memory in mice by using their innate tendency to 
explore new environments.  The maze has three closed arms, or lanes of travel, that are each 
12 inches in length and 1200 from each other and are interconnected. The animal was placed 
into the end of one of the arms and was allowed to freely explore for 5 minutes. The starting 
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arm positions of the mice were chosen at random. 
The movement of the animal inside the Y maze 
was recorded by means of an overhead camera. 
The arms were thoroughly cleaned with 
disinfectant and 70% ethanol to eliminate any 
residual odors of previous mice. The number of 
arm entries were counted and acts as a marker of 
locomotor activity. The number of spontaneous 
alternations, as defined by entry into three 
different arms in sequence (triad), were 
considered as a measure of working memory. Spontaneous alternations was calculated from 
the following equation:  
% Spontaneous alternations = ((number of triads / (total number of arm entries-2)) X 100.  
2.13 Morris water maze 
 The Morris water maze is a standard test of measuring spatial learning and memory 
in rodents.  Animals were brought to the testing facility in their home cages and allowed to 
acclimate for 1 hour and the water maze was prepared.  Briefly, a 4 foot diameter galvanized 
tank was filled to a depth of 12 inches with 23-25°C water.  A 10 cm escape platform was 
submerged 1 cm below the surface of the water in a fixed location.  External navigation cues 
were placed outside the arena. The animal was placed in the water and was allowed 1 minute 
to freely explore the tank.  If the animal does not find the escape platform within 1 minute, it 
was gently guided to the location of the platform.  Once on the platform, the animal was given 
60 seconds to rest within view of the external cues. The location trial was repeated 4 times a 
day for 5 days. The order of the location where the mice were placed in water during the 
acquisition trial was changed every day. The following order was employed to test the animals 
each day.  
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Latency to locate the escape platform was measured.  A memory retention test was performed  
24 hours following the final learning trial. Platform was removed and the animal was dropped 
from a novel location (SW quadrant) and was allowed to explore the tank for 60 seconds. 
Time spent in the target quadrant (where the platform was initially located) and distance 
traveled in the target quadrant were measured. The movement of the animal inside the maze 
was recorded by means of an overhead camera. 
  
Table 1: Locations where the mice were dropped in the water maze at different trails during 
each day 
Trial 1 Trial 2 Trial 3 Trial 4
Day 1 N E SE NW
Day 2 SE N NW E
Day 3 NW SE E N
Day 4 E NW N SE
Day 5 N SE E NW
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2.14 Genotyping 
 Tails were collected from the mice just before weaning. 400 µl of lysis buffer and 2.5 
µl of proteinase K was added to the tail samples and were digested overnight in a water bath 
at 550C. On the following day, 300 µl of 6M sodium chloride was added and the tubes were 
spun at 10,000 rpm for 5 min. 300 µl of supernatant was carefully transferred into a tube 
without collecting the debris. 350 µl of isopropanol was added and the tubes were allowed to 
sit for 10 min, followed by centrifugation at 10,000 rpm for 5 min. The supernatants were 
discarded and the tubes were air dried. The pellet was washed with 70% ethanol and 
centrifuged at 10,000 rpm for 10 min. The supernatants discarded and air dried to completely 
remove traces of ethanol. The pellet was dissolved in 35 µl of TE buffer and the concentration 
of DNA was recorded using a spectrophotometer. 100 ng of DNA was used for PCR to amplify 
Tat gene. The following forward and reverse primer sequences were used ( Fwd: 5’-
Figure 4: Diagram of Morris water maze. NW, NE, SW and SE represent northwest, 
northeast, southwest and southeast quadrants, respectively. 
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GCGGATCCATGGAGCCAGTAGATCCTA-3’ ; Rev: 5’-
GCGAATTCTCATTGCTTTGATAGAGAAACTTG-3’ ). The PCR conditions that were used 
are as follows; denaturation at 950C for 5 min; 40 cycles of denaturation ay 950C for 45sec, 
annealing at 540C and extension at 720C for 30 sec. 8 µl of amplified product was mixed with 
2 µl of loading dye and was loaded into wells of 2% agarose gel. The gel was run at 80 V for 
1 hour. Tat positive mice were identified by the presence of a band at 220 bp that corresponds 
to length of Tat.  
2.15 Statistical analysis 
 Statistical analyses was performed using Graphpad Prism and Statistical package for 
social sciences (SPSS, version 23 for windows, IBM, Armonk, NY). For experiments involving 
cell culture, statistical analysis was performed to represent the data in mean ± SE values. 
Results were based on at least three independent experiments with each experiment 
performed in triplicate. For experiments involving mice, values are represented as mean of all 
mice in a particular group. For the comparison between mock/control group and treatments, 
two-tailed student’s t-test and one-way ANOVA were used to calculate p-value. Dunnet’s post-
hoc and Tukey’s LSD post-hoc were performed appropriately as mentioned in the figure 
legends. For experiments involving morrris water maze, two-way ANOVA with Tukey’s post-
hoc analysis was performed to calculate the significance for acquisition trial. p<0.05 was 
considered as statistically significant.  
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S. No Name Cat. No. Company Dilution
1 NK-κB p65 Rabbit mab 8242S Cell signaling (1:4000)
2 Phospho-IκBα (Ser32) (14D4) Rabbit mab 5209S Cell signaling (1:2000)
3 Phospho-Akt (Ser473) (D9E) XP® Rabbit mAb 4060S Cell signaling (1:2000)
4 Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP® Rabbit mAb 4511S Cell signaling (1:2000)
5 Phospho-c-Jun (Ser73) (D47G9) XP® Rabbit mAb 3270S Cell signaling (1:4000)
6 p-JNK Antibody (G-7) sc-6254 Santa cruz (1:1500)
7 JNK Antibody (D-2) sc-7345 Santa cruz (1:1500)
8 Phospho-Synapsin (Ser9) Antibody 2311S Cell signaling (1:2000)
9 Synaptophysin (D35E4) XP® Rabbit mAb 5461S Cell signaling (1:2000)
10 PSD95 (D74D3) XP® Rabbit mAb 3409S Cell signaling (1:2000)
11 Anti-Arg 3.1 antibody ab23382 Abcam (1:2000)
12 SHANK2 Antibody 12218S Cell signaling (1:2000)
13 Anti-BDNF antibody ab108319 Abcam (1:2000)
14 Anti-CNTF antibody ab46172 Abcam (1:2000)
15 Phospho-CaMKII (Thr286) (D21E4) Rabbit mAb 12716S Cell signaling (1:2000)
16 GAPDH (D16H11) XP® Rabbit mAb 5174S Cell signaling (1:4000)
17 Lamin B Antibody (C-20) sc-6216 Santa cruz (1:1500)
18 Mouse IgG (conjugated with alexa fluor 555) 4409 Cell signaling (1:2000)
19 Rabbit IgG (conjugated with alexa fluor 488) 4340 Cell signaling (1:2000)
20 Rabbit anti-IL-6 ab6672 Abcam (1:500)
21 Rabbit anti-IL-8 sc-7922 santacruz (1:500)
22 Rabbit anti-CCL5 PA1-84182 Thermo Fisher (1:500)
23 Anti-mouse IgG, HRP-linked Antibody 7076S Cell signaling (1:2000)
24 Anti-rabbit IgG, HRP-linked Antibody 7074S Cell signaling (1:2000)
Table 3: List of antibodies and optimum dilutions 
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CHAPTER 3 
ROLE OF HIV-1 TAT IN THE EXPRESSION OF VARIOUS PRO-INFLAMMATORY 
CYTOKINES/CHEMOKINES AND THEIR UNDERLYING MECHANISM(S) 
3.1 Introduction 
 One of the hallmarks of neurodegeneration is inflammation in the central nervous 
system (CNS). A major factor leading to neuroinflammation is the dysregulation of cytokines 
and chemokines in the CNS. Several pro-inflammatory cytokines, IL-1β, IL-6, IL-8 and TNF-α 
have been implicated in neuroinflammation, leading to several neurodegenerative diseases 
including Alzheimer’s disease (Forloni, Mangiarotti et al. 1997), Parkinson’s disease (PD) 
(Nagatsu and Sawada 2005), multiple sclerosis (Maimone, Guazzi et al. 1997) and HIV 
associated neurocognitive disorders (HAND) (Kaul, Garden et al. 2001). In particular, in HIV 
infection, elevated levels of cytokines correlate with the degree of HAND (Yuan, Qiao et al. 
2013). While IL-6, IL-8 and CCL5 have been extensively studied for their role in AD and PD, 
not much is known about the role of these cytokines/chemokines in HAND. 
Human immunodeficiency virus-1 (HIV-1) enters the brain through blood brain barrier 
(BBB) early after the infection (Resnick, Berger et al. 1988). Prolonged infection of central 
nervous system further leads to various neurological complications including HIV-associated 
dementia (HAD). Introduction of combined Anti Retro Viral therapy (cART) has significantly 
reduced the incidence of HAD and increased the life expectancy of people infected with HIV. 
Increase in the life span of people resulted in the development of less severe forms of 
cognitive dysfunctions, including asymptomatic neurocognitive impairment (ANI) and Mild 
neurocognitive disorder (MND). The collection of these neurological deficits including HAD 
are referred HAND (Sacktor, Lyles et al. 2001). The neurotoxicity of HIV-1 has been attributed 
to the virus itself or the viral proteins shed after the infection via several mechanisms including 
production of cytokines/chemokines. The role of two HIV proteins, HIV-1 Tat and gp120 has 
been extensively studied for their role in neuroinflammation. We and others have recently 
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shown that gp120 induces pro-inflammatory cytokines and reactive oxygen species in 
different cells of the brain and thereby contributes to HAND (Yeung, Pulliam et al. 1995, Shah, 
Verma et al. 2011). In particular, presence of HIV-1 Tat has been reported in postmortem CNS 
tissue (hippocampus) of the HIV-1 infected patients, which underscores the significance of 
HIV-1 Tat in the HIV neuropathogenesis (Kruman, Nath et al. 1999). Furthermore, HIV-1 Tat 
has also been shown to promote the release of several pro-inflammatory cytokines and ROS 
from different brain cells (Nath, Conant et al. 1999, Toborek, Lee et al. 2003). 
HIV-1 Trans activator of transcription (HIV-1 Tat or Tat) is an accessory viral protein 
produced at a very early stage of HIV-1 replication. It binds to the Tat associated region on 
the viral RNA and increases the replication of the virus (Dayton, Sodroski et al. 1986, Roy, 
Delling et al. 1990). Tat increases the transcription of HIV-1 genome by greater than 100 fold 
(Cann, Rosenblatt et al. 1985). Tat has been shown to be toxic to the mice when injected into 
the cerebroventricular region (Gourdou, Mabrouk et al. 1990, Jones, Olafson et al. 1998).  The 
neurotoxicity of Tat is attributed to various mechanisms such as, over excitation of the neurons 
via N-methyl-D-aspartate receptor (Magnuson, Knudsen et al. 1995, Nath, Psooy et al. 1996, 
New, Maggirwar et al. 1998, Haughey, Nath et al. 2001) apoptosis of the neurons by 
increasing intracellular calcium levels (Mayne, Holden et al. 2000, Self, Mulholland et al. 2004) 
and disrupting the normal function of electron transport chain (Norman, Perry et al. 2007). It 
also affects the function of dopamine neurotransmission by deregulating the functions of 
dopamine transporter and vesicular monoamine transporter (Midde, Gomez et al. 2012). In 
addition to its direct effect on neurons, Tat has been shown to exhibit a bystander effect on 
neurons by promoting the release of several pro-inflammatory cytokines/chemokines, nitric 
oxide synthase and quinolinic acid from astrocytes and microglia (Li, Galey et al. 2005). Tat 
also affects the integrity of blood brain barrier by disrupting the tight junction proteins, by 
inducing oxidative stress (Price, Uras et al. 2006, Banerjee, Zhang et al. 2010) and apoptosis 
in brain microvascular endothelial cells (Andras, Pu et al. 2005).  
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Astrocytes comprise of majority of cells in the brain and occupy more than 50% of the 
brain volume. They also represent an important reservoir for the production of various 
mediators of inflammation, particularly in response to HIV-1 (Thompson, McArthur et al. 2001, 
Minagar, Shapshak et al. 2002). They play important roles in many brain functions, including 
the maintenance of homeostasis of the neurons, promoting the release of various 
neurotrophic factors, modulation of neuronal activity and regulation of synaptic plasticity 
(Halassa and Haydon 2010, Navarrete, Perea et al. 2012). Furthermore, they function as 
immune cells in the CNS by releasing myriad of cytokines/chemokines such as interleukins, 
(IL-1β, IL-6, IL-8), Interferons (IFNs) and Chemokine ligands (CCLs) including CCL5 
(Anderson and Swanson 2000). During viral infection, cytokines/chemokines directs the 
lymphocytes and monocytes to the site of inflammation (Appay and Rowland-Jones 2001). 
Post-mortem studies of brain samples of HIV-1 infected patients showed that a small portion 
of astrocytes are restrictively infected with the virus (Gorry, Ong et al. 2003). In a previous 
study by Churchill et al, they have demonstrated that in vivo astrocyte infection by HIV-1 
occurs to a greater extent than previously known (Churchill, Wesselingh et al. 2009). A sub-
population of astrocytes that are latently infected with HIV-1 undergoes apoptosis that 
correlates with the extent of HAND (Thompson, McArthur et al. 2001). The viral infection of 
astrocytes results in the production of viral proteins, which are neurotoxic. Tat has been shown 
to be produced by the astrocytes which were productively infected by the HIV-1(Dou, 
Morehead et al. 2006). Tat has been shown to promote the up-regulation of many cytokines 
from astrocytes including MCP-1, IL-8, IL-6 and TNF-α (Chen, Mayne et al. 1997, Nath, 
Conant et al. 1999, Kutsch, Oh et al. 2000). 
Although HIV-1 Tat has been shown to induce cytokines/chemokines in astrocytes, 
the mechanism(s) remains largely unknown. The present study was undertaken to conduct a 
systematic study of cytokine/chemokine expressions, time kinetics and identification of 
various transcription factors and upstream signaling molecules.  
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3.2 Results 
3.2.1 HIV-1 Tat induces the expression of various cytokines/chemokines in SVG 
astrocytes 
Previous studies have demonstrated the expression of various cytokines/chemokines 
by HIV-1 Tat from astrocytes. We wanted to determine the expression of a panel of 
cytokines/chemokines that are upregulated/downregulated by HIV-1 Tat. We tested the 
mRNA expressions of 9 different cytokines/chemokines at 6 hours post transfection. We found 
that the expressions of IL-6, IL-8 and CCL5 were significantly upregulated (more than 10 fold) 
and the expression of MCP-1 was slightly increased whereas the expressions of IL-1β, TNF-
α, MIP-1 and IL-10 remained unaffected by HIV-1 Tat compared to others (Fig 5). We then 
tested for the protein levels of these different cytokines at 48 h post transfection. We observed 
significant increase in the expression levels of IL-6, IL-8 and CCL5. Therefore, all the further 
 
Figure 5: HIV-1 Tat-mediated cytokine/chemokine expression in SVG astrocytes: 
0.7x106 million cells were transfected with 0.3 µg of plasmid encoding HIV-1 Tat using 
lipofectamine 2000. The cells were harvested 6 hours post-transfection.  The mRNA 
expressions were measured using real time RT-PCR and levels are presented as fold 
difference between HIV-1 Tat transfected cells and mock-transfected control. Each bar 
represents mean ± SE. The statistical significance was calculated using student’s t-test 
and ** denotes p-value ≤ 0.01 and * denotes p-value ≤ 0.05. 
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studies were focused on the IL-6, IL-8 and CCL5 expression and delineation of the 
mechanistic pathway(s) involved in their expression. 
3.2.2 HIV-1 Tat induces the expression of IL-6 in a time dependent manner at mRNA and 
protein level 
A myriad of pro-inflammatory cytokines including IL-6 has been shown to be elevated 
in the CSF of individuals infected with HIV-1. The role of HIV-1 Tat in the up-regulation of this 
cytokine from astrocytes has been shown in previous studies. However, the molecular 
mechanisms behind the up regulation of this cytokine remains largely unknown. In the present 
study, we sought to determine the molecular mechanisms behind the up regulation of this 
cytokine by HIV-1 Tat in astrocytes. To this end, we employed the transfection approach, 
whereby the astrocytes were transfected with plasmid encoding HIV-1 Tat. Transfection 
efficiency was monitored by setting a parallel transfection with plasmid encoding green 
florescence protein (GFP). The efficiency as measured and analyzed by BD FACScanto flow 
cytometer ranged in between 50-65% (data not shown). We first performed a time kinetics 
experiment to determine the peak expression levels of IL-6 at mRNA and protein levels. 
Compared to mock transfected cells, the levels of IL-6 mRNA increased as early as 1 h, 
peaked at 6 h and declined steadily until 72 h (Fig 6A). The peak expression levels of IL-6 
after 6 h of transfection was found to be 29.2 ± 2.5 and 26.2 ± 1.7 fold, respectively.  
To determine the protein levels of IL-6, a multiplex cytokine assay was performed at 
indicated time points (6 h, 12 h, 24 h, 48 h, 72 h and 96 h). The levels of IL-6 protein started 
to increase significantly from 6 h (6.10 ± 0.36 ng/ml vs 2.10 ± 0.19 ng/ml) after transfection 
and gradually increased until 96 h (14.08 ± 1.59 ng/ml vs 1.79 ± 0.22 ng/ml) where it showed 
the maximum increase (until observation period) compared to the mock transfected cells (Fig 
6B). There was not a significant change in IL-6 protein levels in mock transfected cells. These 
results clearly demonstrate that HIV-1 Tat induces the expression of IL-6 from astrocytes in a 
time dependent manner at the level of mRNA as well as protein level. These results were also 
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confirmed in primary astrocytes isolated from two fetal brains collected after abortion where 
treatment with HIV-1 Tat protein (200 ng/ml) for 2 hours showed significant IL-6 up-regulation 
(10.2 ± 3.4 fold) (Fig 6C).  
   
Figure 6: HIV-1 Tat induces time dependent expression of IL-6 in SVG astrocytes. Seven 
hundred thousand SVG astrocytes were transfected with 0.3 μg of HIV-1 Tat plasmid using 
Lipofectamine 2000. (A) Cells were harvested at 1, 3, 6, 12, 24, 48 and 72 hours and total RNA was 
isolated. The expression levels of IL-6 were determined by real time RT-PCR. The values 
represented are normalized to their mock-transfected controls. (B) The concentrations of IL-6 in cell 
culture supernatants were measured at 6, 12, 24, 48, 72 and 96 hours after transfection by multiplex 
cytokine assay. Open bars and closed bars represent protein concentrations of mock- and HIV-1 
Tat- transfected cells, respectively. Each experiment was done at least in triplicate and each bar 
represents the ± SE of three individual experiments. (C) Primary astrocytes from 2 independent 
donors were treated with 200 ng/ml of Tat protein for 2 hours and total RNA was isolated. The 
expression level of IL-6 was determined by real time RT-PCR. Statistical analyses was performed by 
Student’s t-test and ** denotes p-value of ≤ 0.01 
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3.2.3 HIV-1 Tat induces the expression of IL-8 in a time dependent manner at mRNA and 
protein level 
 Similar to IL-6, we measured the expression levels of IL-8 at different time points at 
both mRNA and protein. The time kinetics experiment showed an increase in the mRNA 
expression levels of IL-8 as early as 1 hour post transfection. The mRNA expression continued 
to increase until 6 hours, where is peaked and then started to gradually decrease until last 
time point (72h) of the observation period. The peak expression of IL-8 was found to be 26.2 
± 1.7 fold compared to mock transfected cells (Fig 7A). We then performed bioplex to quantify 
the expression levels of IL-8 at protein level at various time points (6 h, 12 h, 24 h, 48 h, 72 h 
and 96 h). The expression of IL-8 started to increase from 6 h post transfection (0.172 ± 0.01 
compared to 0.112 ± 0.006 ng/ml in controls), continued gradually until 96 h (0.813 ± 0.09 
ng/ml compared to 0.185 ± 0.005 ng/ml in controls), last time point of the observation period 
(Fig 7B). There was not a significant change in IL-8 protein level in mock transfected cells. 
These results clearly demonstrate that HIV-1 Tat induces the expression of IL-8 from 
astrocytes in a time dependent manner at the level of mRNA as well as protein level. These 
results were also confirmed in primary astrocytes isolated from two fetal brains collected after 
abortion where treatment with HIV-1 Tat protein (200 ng/ml) for 2 hours showed significant IL-
8 up-regulation (17.3 ± 5.2 fold) (Fig 7C). 
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Figure 7: HIV-1 Tat induces time dependent expression of IL-8 in SVG astrocytes. Seven 
hundred thousand SVG astrocytes were transfected with 0.3 μg of HIV-1 Tat plasmid using 
Lipofectamine 2000. (A) Cells were harvested at 1, 3, 6, 12, 24, 48 and 72 hours and total RNA was 
isolated. The expression levels of IL-8 were determined by real time RT-PCR. The values 
represented are normalized to their mock-transfected controls. (B) The concentrations of IL-8 in cell 
culture supernatants were measured at 6, 12, 24, 48, 72 and 96 hours after transfection by multiplex 
cytokine assay. Open bars and closed bars represent protein concentrations of mock- and HIV-1 
Tat- transfected cells, respectively. Each experiment was done at least in triplicate and each bar 
represents the ± SE of three individual experiments. (C) Primary astrocytes from 2 independent 
donors were treated with 200 ng/ml of Tat protein for 2 hours and total RNA was isolated. The 
expression level of IL-8 was determined by real time RT-PCR. Statistical analyses was performed by 
Student’s t-test and ** denotes p-value of ≤ 0.01 
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3.2.4 HIV-1 Tat induces the expression of CCL5 in a time dependent manner at mRNA 
and protein level 
In view of the findings that elevated CCL5 has been detected in the CSF of HIV-1 
infected individuals suffering from HAD and that HIV-1 Tat induces CCL5 production in 
astrocytes (Kelder, McArthur et al. 1998, El-Hage, Podhaizer et al. 2011), we sought to 
investigate the underlying mechanism(s) responsible for HIV-1 Tat-mediated CCL5 
expression in astrocytes. We observed elevated CCL5 mRNA level within 1 h of transfection 
(17.09 ± 0.59 fold), which gradually declined in a time-dependent manner over 72 h 
observation period (Fig. 8A). Similarly, the expressions at protein levels were measured in cell 
culture supernatants at various time intervals (6 h, 12 h, 24 h, 48 h, 72 h and 96 h) (Fig. 8B). 
The protein levels of CCL5 showed significant increase as early as 6 h (0.48 ± 0.04 ng/ml vs 
0.04 ± 0.001 ng/ml in control). The peak CCL5 expression was observed at 48h post-
transfection (2.04 ± 0.17 ng/ml compared to 0.27 ± 0.01 ng/ml in controls) followed by time-
dependent decrease over 96 h observation period (Fig. 8B). These results indicate that HIV-
1 Tat-mediated induction of CCL5 expression follows a time-dependent kinetics at both mRNA 
as well as protein levels. 
  
40 
 
  A B
0
500
1000
1500
2000
2500
6H 12H 24H 48H 72H 96H
C
C
L
5
 C
o
n
c
 (
p
g
/m
l)
Time post Tat transfection 
Mock Tat
**
**
**
**
**
**
0
5
10
15
20
Mock 1H 3H 6H 12H 24H 48H 72H
R
e
la
ti
v
e
 C
C
L
5
 e
x
p
re
s
s
io
n
Time post-transfection (Hours)
** **
**
**
**
**
Figure 8: HIV-1 Tat induces time dependent expression of CCL5 in SVG astrocytes. Seven 
hundred thousand SVG astrocytes were transfected with 0.3 μg of HIV-1 Tat plasmid using 
Lipofectamine 2000. (A) Cells were harvested at 1, 3, 6, 12, 24, 48 and 72 hours and total RNA was 
isolated. The expression levels of CCL5 were determined by real time RT-PCR. The values 
represented are normalized to their mock-transfected controls. (B) The concentrations of CCL5 in cell 
culture supernatants were measured at 6, 12, 24, 48, 72 and 96 hours after transfection by multiplex 
cytokine assay. Open bars and closed bars represent protein concentrations of mock- and HIV-1 Tat- 
transfected cells, respectively. Each experiment was done at least in triplicate and each bar represents 
the ± SE of three individual experiments. Statistical analyses was performed by Student’s t-test and ** 
denotes p-value of ≤ 0.01 
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3.2.5 HIV-1 Tat-mediated induction of intracellular protein expression of various 
cytokines/chemokines 
 In order to further confirm the findings observed at mRNA and protein levels, we 
employed immunocytochemistry on the HIV-1 Tat-transfected astrocytes to visualize the 
production of IL-6, IL-8 and CCL5. The cells were incubated with a cocktail of GFAP and IL-6 
or IL-8 or CCL5 specific antibodies. These proteins were visualized by staining with a 
secondary antibody labeled with Alexafluor 488 and Alexafluor 555 for GFAP and the cytokine, 
respectively. DAPI staining was performed to visualize the nucleus of the cells. The results 
clearly show that IL-6, IL-8 and CCL5 are increased in HIV-1 Tat-transfected cells when 
compared with mock-transfected and untransfected cells (Fig. 9-11). Our results also indicate 
that astrocyte marker GFAP did not significantly change with either control or mock or HIV-1 
Tat transfection (Fig. 9-11). The intensity of IL-6 over GFAP was 3 ± 0.21 fold higher in HIV-1 
Tat-transfected cells when compared to the control cells (Fig. 9j). Similarly, the intensity of IL-
8 was 2.46 ± 0.28 fold (Fig. 10t) and intensity of CCL5 was 2.6 fold more when compared to 
the untransfected cells (Fig. 11j). The change in intensities of either IL-6 or IL-8 or CCL5 was 
not significant in mock-transfected cells when compared to the untransfected cells. 
  
42 
 
 
  
J 
Figure 9: Immunocytochemistry of IL-6 mediated by HIV-1 Tat in astrocytes: (a-i) Five hundred 
thousand SVG astrocytes were grown on a cover slip and transfected with plasmid encoding HIV-1 Tat. The 
over expression of IL-6 by HIV-1 Tat (g-i) was compared with control cells (a-c) and mock-transfected cells 
(d-f). The cells were costained with a mixture of antibodies against GFAP (red) and IL-6 (green). The nucleus 
was stained blue using 4′,6-diamidino-2-phenylindole (DAPI). The images for different fluorophores were 
obtained using an inverted confocal microscope. The quantification of IL-6 was done using imageJ software 
(j). Each experiment was done at least in triplicate and each bar represents the ± SE of three individual 
experiments. Statistical analyses was performed by Student’s t-test and ** denotes P-value of ≤ 0.01. 
J 
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Figure 10: Immunocytochemistry of IL-8 mediated by HIV-1 Tat in astrocytes: (k-s) Five hundred 
thousand SVG astrocytes were grown on a cover slip and transfected with plasmid encoding HIV-1 Tat. 
The over expression of IL-6 and IL-8 by HIV-1 Tat (q-s) was compared with control cells (k-m) and mock-
transfected cells (n-p). The cells were costained with a mixture of antibodies against GFAP (red) and 
IL-8 (green). The nucleus was stained blue using 4′,6-diamidino-2-phenylindole (DAPI). The images for 
different fluorophores were obtained using an inverted confocal microscope. The quantification of IL-8 
was done using imageJ software (t). Each experiment was done at least in triplicate and each bar 
represents the ± SE of three individual experiments. Statistical analyses was performed by Student’s t-
test and ** denotes P-value of ≤ 0.01. 
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Figure 11: Immunocytochemistry of CCL5 induced by HIV-1 Tat in astrocytes: (A–I) 
SVGA astrocytes were grown on a cover slip before transfecting with HIV-1 Tat plasmid. 
Untransfected control (A–C) and mock-transfected cells (D–F) were used to compare the up-
regulation of CCL5 in cells transfected with HIV-1 Tat (G–I). The cells were stained with the 
primary antibodies against CCL5 and GFAP and secondary antibody labeled with Alexafluor 
555 (GFAP) and Alexafluor 488 (CCL5). Finally the cover slips were mounted on medium 
containing DAPI to stain the nucleus. The merge panels represent the co-localization of CCL5 
with GFAP. The images were captured using inverted confocal microscope, Leica TCS SP5 
II. (J) The intensity of CCL5 over GFAP was calculated using imageJ software. Student’s t-
test was employed to calculate the significance and ** denotes the p-value ≤0.01. 
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3.2.7 Activation of NF-κB by HIV-1 Tat in SVG astrocytes 
After determining the up-regulation of IL-6, IL-8 and CCL5 in astrocytes by HIV-1 Tat, 
we wanted to determine the underlying signal transduction pathway(s). We initially looked at 
the role of nuclear factor kappa B (NF-κB) in the up-regulation of HIV-1 Tat mediated IL-6, IL-
8 and CCL5 in the astrocytes as these cytokines/chemokines contain binding sites for NF-κB 
(Libermann and Baltimore 1990, Kunsch and Rosen 1993). NF-κB is a master transcription 
factor involved in many inflammatory processes, including the up-regulation of several pro-
inflammatory cytokines/chemokines in several different systems (Shea, Beehler et al. 1996). 
Canonical activation of NF-κB occurs through the phosphorylation of IκB kinase (IKK), 
generally achieved though the activation of upstream signaling molecules or signals from 
outside the cell. Activated IKK phosphorylates serine residues located on the regulatory 
domain of IkappaB (IκB). Phosphorylation of IκB results in its detachment from NF-κB complex 
and is degraded by proteasomes through the process of ubiquitination. The active NF-κB 
complex is released and goes into the nucleus to bind to specific binding sites on DNA to turn 
on the transcription of various genes, including the pro-inflammatory cytokines/chemokines 
(Lawrence 2009).   
 Previous reports have indicated the role of NF-κB in the production of cytokines by 
HIV-1 Tat in astrocytes and other cells (Nicolini, Ajmone-Cat et al. 2001, Nookala, Shah et al. 
2013). In order to confirm the activation of NF-κB by HIV-1 Tat, we transfected the cells with 
plasmid encoding HIV-1 Tat and measured the translocation of p65 (indicator of NF-κB 
activation) into the nucleus. After confirming the activation of NF-κB by HIV-1 Tat, we 
performed time kinetics (3h, 6h, 9h and 12h) to determine the peak increase in p65 
translocation. Compared to mock-transfected cells, p65 translocation in HIV-1 Tat-transfected 
cells started to increase as early as 3 hours, peaked at 9 hours (2.04 ± 0.04 fold) and remained 
constant until the indicated time point (12 hours) (Fig. 12A). We used GAPDH and LaminB as 
loading controls for cytoplasmic and nuclear fractions, respectively and the data was 
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normalized to them. We also confirmed the activation of NF-κB in primary astrocytes obtained 
from two different donors by measuring p-IκBα expression after treatment with HIV-1 Tat 
protein. The level of p-IκBα increased as early as 5 minutes and peak level was observed at 
20 minutes post-treatment (Fig. 12B). These results demonstrate that HIV-1 Tat induces the 
activation of NF-κB transcription in astrocytes. 
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Figure 12: HIV-1 Tat mediated activation of NF-κB in astrocytes: (A) SVG astrocytes were either 
mock-transfected or transfected with HIV-1 Tat plasmid and translocation of p65 was measured at 3, 
6, 9 and 12 hours. Open bars and closed bars represent cytoplasm and nuclear fractions, respectively. 
(B) Primary astrocytes were treated with 200 ng/ml Tat protein and p-IκBα protein levels were 
measured from 0 minutes to 60 minutes. The bar graph represents the mean values obtained from 
two independent donors. Each experiment was done at least in triplicate and each bar represents 
the ± SE of three individual experiments. Statistical analyses was performed by one-way ANOVA and 
** denotes P-value of ≤ 0.01 
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3.2.8 Involvement of NF-κB in HIV-Tat mediated up-regulation of IL-6, IL-8 and CCL5 in 
astrocytes 
After establishing that HIV-1 Tat-induced p65 translocation in SVG astrocytes, we 
wanted to determine if NF-κB was involved in up-regulation of cytokines/chemokines. To 
determine this, we employed pharmacological inhibitor approach. We used BAY11-7082 or 
SC-514, those specifically inhibit IκB kinase, enzyme responsible for the phosphorylation of 
IκBα.  The starting dose of the inhibitors was based on IC50 values from previous literature 
and was further optimized based on their effect on cell viability (data not shown) (Kishore, 
Sommers et al. 2003, Strickson, Campbell et al. 2013). Cells were pretreated with 10 μM 
concentration of specific inhibitory kinase kinase (IKK) inhibitor, BAY11-7082 (IC50=11.2 µM) 
or SC-514 (IC50=14.5 µM), 1 hour prior to transfection with HIV-1 Tat. The expression levels 
of IL-6, IL-8 and CCL5 were determined at 6 hours and 48 hours post transfection for mRNA 
and protein respectively. BAY11-7082 decreased the expression of IL-6 by 47.1 ± 6.1% and 
63.3 ± 4.7% at mRNA and protein levels respectively (Fig. 13A, B). Similarly, the expression 
levels of IL-8 were decreased by 41.1 ± 7.5% and 47.4 ± 4.7% at the levels of mRNA and 
protein respectively (Fig. 13C, D). Furthermore, use of 10 µM concentration of SC-514 
decreased the expression of CCL5 by 46.6 ± 14.2% at the level of mRNA and by 47.7 ± 11.9% 
at the level of protein, respectively (Fig. 14E, F).  
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Figure 13: Involvement of NF-κB in HIV-Tat mediated up-regulation of IL-6 and IL-8: SVG 
astrocytes were pretreated with 10 μM concentration of NF-κB inhibitor (BAY11-7082) 1 hour 
prior to the transfection. The expressions of IL-6 and IL-8 were determined at 6 hours and 48 
hours post transfection for mRNA (A, C) and protein (B, D), respectively. The values represented 
are normalized their mock-transfected controls. Each experiment was done at least in triplicate 
and each bar represents the ± SE of three individual experiments. Statistical analyses was 
performed by one-way ANOVA and ** denotes P-value of ≤ 0.01. 
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To confirm the results of the pharmacological inhibitor, we employed siRNA approach 
to individually knock down major subunits of NF-κB which include p50 (NF-κB1) and p65 
(RelA) subunits. 50 nmoles of siRNA was used to knock down the individual subunits and the 
efficiency of knock down was previously verified (Gangwani, Noel et al. 2013). Our results 
show that p65, but not p50 knock down decreased the expression of IL-6 by 40.8 ± 3.8% and 
48.2 ± 5.8% at mRNA and protein levels respectively (Fig. 15A, B). Similar to the inhibitor 
results, knock down of p65 decreased the expression levels of IL-8 by 60.1 ± 4.7% at the level 
of mRNA and by 69.3 ± 2.6% at the level of protein (Fig. 15C, D). Knock down of the p50 
subunit of NF-κB did not affect the expression levels of IL-6 and IL-8 at either level of mRNA 
or protein. Knock down of p50 subunit of NF-κB did not have any effect on the expression 
E F
0
5
10
15
20
25
30
Mock Tat SC514 Tat +
SC514
R
e
la
ti
ve
 
C
C
L
5
 e
x
p
re
s
s
io
n *
0
500
1000
1500
2000
Mock Tat SC514 Tat +
SC514
C
C
L
5
 C
o
n
c
 (
p
g
 /
 m
l)
* *
Figure 14: Involvement of NF-κB in HIV-1 Tat mediated production of CCL5 from astrocytes: (E, 
F) SVG astrocytes were treated with 10 µM of NF-κB inhibitor (SC514) prior to transfection with plasmid 
encoding HIV-1 Tat. The expression of CCL5 at the mRNA and protein levels were measured at 6 h and 
48 h post-transfection by using RT-PCR (E) and multiplex cytokine assay (F), respectively. The values 
represented for mRNA are expressed relative to the mock-transfected controls. Each experiment was 
performed in triplicate and each bar in the figure represents the mean ± SE of at least three individual 
experiments. One-way ANOVA was used to perform the statistical analysis and ** denotes p-value ≤0.01 
and * denotes p-value of ≤0.05. 
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levels of IL-6, but has increased the expression levels of IL-8 at mRNA and protein. However, 
knock down of p65 and p50 subunits have partially decreased the expression levels of CCL5 
at both mRNA and protein levels. Knock down of p65 has decreased the expression of CCL5 
by 42.8 ± 8.3% at mRNA and 48.9 ± 6.07% at protein level respectively. Similarly, knock down 
of p50 subunit has decreased the expression of CCL5 by 69.8 ± 10.5% at mRNA and 68.9 ± 
4.86% at protein level, respectively (Fig. 15E, F).  The results of siRNA were in accordance 
with the inhibitor results and show that NF-κB played an important role in the up-regulation of 
cytokines/chemokines mediated by HIV-1 Tat in astrocytes. 
  
52 
 
  
Figure 15: Involvement of NF-κB in HIV-Tat mediated up-regulation of cytokines/chemokines: 
cells were transfected with the siRNA followed by Tat transfection as mentioned in the Materials and 
Methods. The expression of IL-6, IL-8 and CCL5 was determined at 6 hours and 48 hours post 
transfection for mRNA (A, C, E) and protein (B, D, E), respectively. The values represented for mRNA 
are expressed relative to the mock-transfected controls.  Each experiment was done at least in triplicate 
and each bar represents the ± SE of three individual experiments. Statistical analyses was performed by 
one-way ANOVA and ** denotes P-value of ≤ 0.01. 
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We also measured the translocation of p65 into the nucleus upon pretreatment with 
BAY11-7082. The translocation of p65 decreased by 32 ± 3.3% in BAY11-7082 pretreated 
cells compared to the HIV-1 Tat-transfected cells (Fig. 16A). 
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Figure 16: Involvement of NF-κB in HIV-1 Tat mediated induction of 
cytokines/chemokines: Astrocytes were either mock-transfected or transfected with HIV-1 
Tat plasmid for a duration of 6 hours and translocation of p65 was measured. Each experiment 
was done at least in triplicate and each bar represents the ± SE of three individual experiments. 
Statistical analyses was performed by one-way ANOVA and ** denotes P-value of ≤ 0.01. 
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3.2.9 Involvement of MAPK Pathway in Induction of cytokines/chemokines by HIV-1 Tat 
After determining the role of NF-κB, we wanted to explore the upstream signaling 
pathways involved in the activation of NF-κB. Various Mitogen-activated protein kinases 
(MAPKs) such as p38 MAPK, ERK MAPK and JNK MAPK are known to activate NF-κB as 
reported previously (Craig, Larkin et al. 2000). We, therefore, used specific pharmacological 
antagonists against p38 MAPK (SB203580), JNK MAPK (SP600125) and ERK MAPK 
(U0126) to verify their involvement.  
3.2.10 Role of p38 MAPK molecules in the Induction of cytokines/chemokines by HIV-1 
Tat. 
p38 mitogen activated-protein kinase (p38 MAPK) is a family of important upstream 
MAPKs that can activate NF-κB and regulate the expression of many cytokine/chemokines. 
To determine the role of p38 MAPK in the up-regulation of IL-6, IL-8 and CCL5 by HIV-1 Tat, 
we used SB203580, a specific inhibitor of p38 MAPK. The starting dose of the inhibitor was 
based on IC50 values from previous literature and was further optimized based on its effect 
on cell viability (data not shown) (Warny, Keates et al. 2000).  Pretreatment of astrocytes with 
10 μM concentration of SB203580 decreased the expression levels of IL-6 by 47.8 ± 4.1% and 
82.4 ± 0.5% at levels of mRNA and protein respectively (Fig. 17A, B). Similarly, pretreatment 
with SB203580 decreased the expression levels of IL-8 by 43.2 ± 5.6% and 66.1 ± 5.8% at 
mRNA and protein levels (Fig. 17C, D). However, pretreatment of astrocytes with SB203580 
did not affect the expression levels of CCL5 at both mRNA and protein levels (Fig. 17E, F).   
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Figure 17: Inhibition of HIV-1 Tat-induced expression of IL-6 and IL-8 but not CCL5 by inhibitor of 
p38 mitogen activated-protein kinase (MAPK): (A-F) Astrocytes were pretreated with 10 μM 
concentration of p38 MAPK inhibitor (SB203580) 1 hour prior to the transfection. (A, C, E) The 
expression levels of IL-6, IL-8 and CCL5 at mRNA were determined by real time RT-PCR at 6 hours post 
transfection. The values represented are normalized to their mock-transfected controls. (B, D, F) The 
protein concentrations of IL-6, IL-8 and CCL5 were determined in the cell culture supernatants at 48 
hours post transfection by multiplex cytokine assay. Each experiment was done at least in triplicate and 
each bar represents the ± SE of three individual experiments. Statistical analyses was performed by one-
way ANOVA and ** denotes P-value of ≤ 0.01. 
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The involvement of p38 MAPK was further confirmed by the fact that HIV-1 Tat-mediated 
increase in phosphorylated p38 levels were decreased by pretreatment with SB203580 (Fig. 
18A).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
p38 MAPK exists in four different isoforms (α/β/γ/δ) of which SB203580 affects only 
p38α and p38β isoforms of p38 but not the other two isoforms (p38γ and p38δ) (Lee, Kassis 
et al. 1999). In order to validate the roles of p38α and p38β and also to determine the roles of 
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Figure 18: HIV-1 Tat mediated phosphorylation of p38 is inhibited by 
SB203580: Astrocytes were either mock-transfected or transfected with 
HIV-1 Tat plasmid for a duration of 6 hours and p-p38 levels were 
measured in whole cell extracts. A representative Western blot is shown 
in the figure. Each experiment was done at least in triplicate and each bar 
represents the ± SE of three individual experiments. Statistical analyses 
was performed by one-way ANOVA and ** denotes p-value of ≤ 0.01. 
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the other two isoforms in the up-regulation of IL-6, IL-8 and CCL5, we individually knocked 
down all the isoforms of p38 (α/β/γ/δ) using siRNA. The gene knock down was generally 
partial (>60%) except in the case of p38β where silencing was complete (Gangwani, Noel et 
al. 2013, Liu, Shah et al. 2014). Knocking down p38β and p38δ isoforms decreased the 
expression of IL-6. Specifically, knock down of p38β decreased the expression of IL-6 by 
42.6 ± 5.6% and 41.4 ± 4.9% at the levels of mRNA and protein, respectively (Fig. 19A, B). 
Further, p38δ knock down decreased the expression of IL-6 by 49.7 ± 3.5% and 43.8 ± 4.3% 
at mRNA and protein levels respectively (Fig. 19C, D). Individual knock down of only p38β 
decreased the expression level of IL-8 by 47.1 ± 6.4% and 36.2 ± 6.4% at the level of mRNA 
and protein respectively (Fig. 19E, F). As expected with the inhibitor results, knock down of 
p38α and p38β and p38γ did not affect the expression levels of CCL5 at the level of both 
mRNA and protein. Surprisingly, knocking down p38δ decreased the expression of CCL5 by 
56.1 ± 5.5% at the level of mRNA and by 43.26 ± 2.21% at the level of protein. 
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Figure 19: Involvement of p38 mitogen activated-protein kinase (MAPK) in the induction of 
IL-6, IL-8 and CCL5 by HIV-1 Tat. (A-F) SVG astrocytes were transfected with siRNA (scrambled 
or p38α or p38β or p38γ or p38δ) for 48 hours. Then they were mock-transfected or transfected 
with plasmid encoding HIV-1 Tat. (A, C, E) The expression levels of IL-6, IL-8 and CCL5 at mRNA 
were determined by real time RT-PCR at 6 hours post transfection. The values represented are 
normalized to their mock-transfected controls. (B, D, F) The protein concentrations of IL-6, IL-8 and 
CCL5 were determined in the cell culture supernatants at 48 hours post transfection by multiplex 
cytokine assay. Each experiment was done at least in triplicate and each bar represents the ± SE 
of three individual experiments. Statistical analyses was performed by one-way ANOVA and ** 
denotes p-value of ≤ 0.01. 
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Of all the p38 isoforms, p38α and p38β are known to activate NF-κB. To see if p38 
MAPK was leading to the activation of NF-κB, we pretreated the astrocytes with SB203580 
and measured p65 translocation into the nucleus. Pretreatment with SB203580 decreased 
the translocation of p65 by 33.9  ±  4.6% compared to HIV-1 Tat-transfected astrocytes without 
the inhibitor (Fig. 20A). To specifically determine if p38β isoform led to the activation of NF-
κB in our model system, we individually knocked down p38β isoform with siRNA and 
measured the translocation of p65 into the nucleus. Knocking down p38β isoform decreased 
p65 translocation by 28.5% ± 3.6% compared to HIV-1 Tat- transfected cells without inhibitor 
(Fig. 21A). 
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Figure 20: HIV-1 Tat mediated activation of NF-κB involves p38 MAPK: (A) 
Astrocytes were either mock-transfected or transfected with HIV-1 Tat plasmid for 
duration of 6 hours and translocation of p65 was measured. A representative 
Western blot is shown in the figure. Each experiment was done at least in triplicate 
and each bar represents the ± SE of three individual experiments. Statistical 
analyses was performed by one-way ANOVA and ** denotes P-value of ≤ 0.01. 
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Figure 21: HIV-1 Tat mediated activation of NF-κB involves p38 MAPK: (A) Astrocytes were 
transfected with p38β siRNA for 48 hours prior to transfection with HIV-1 Tat plasmid. The 
translocation of p65 is measured 6 hours after transfection. Open bars and closed bars represent 
cytoplasm and nuclear fractions, respectively. A representative Western blot is shown in the figure. 
Each experiment was done at least in triplicate and each bar represents the ± SE of three individual 
experiments. Statistical analyses was performed by one-way ANOVA and ** denotes p-value 
of ≤ 0.01. 
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3.2.11 HIV-1 Tat-mediated induction of cytokines/chemokines involves multiple 
transcription factors activated by different upstream signaling molecules 
In view of our results that p38δ knock down decreased IL-6 and CCL5 expression; we 
wanted to determine the possible transcription factors that could be activated by p38δ. 
Activator protein-1 (AP-1) and CCAT enhancer binding proteins (C/CAT), are known to be 
activated by p38δ (Efimova, Broome et al. 2003). There are 6 isoforms of CCAT/enhancer 
binding protein (C/EBP) known in the literature of which p38δ can specifically lead to the 
activation of α and γ isoforms of C/EBP (Lekstrom-Himes and Xanthopoulos 1998). To 
ascertain the involvement of these transcription factors in the up-regulation of 
cytokines/chemokines by HIV-1 Tat, we individually knocked them down using specific siRNA. 
The expressions of cytokines/chemokines at the mRNA and protein levels were measured 6 
h and 48 h post-transfection, respectively. We used scrambled (Scr) siRNA as negative 
control. AP-1 (c-jun component) knock down by siRNA decreased the IL-6 expression by 43.2 
 ±  3.4% and 51.2  ±  6.3% at mRNA and protein level, respectively (Fig. 22A, B). The knock 
down of C/EBPα or C/EBPγ did not affect the expression levels of IL-6 at either level of mRNA 
or protein. Similar to IL-6, the expression of IL-8 was not affected by the knock down of 
C/EBPα or C/EBPγ. Even though knock down of p38δ did not affect the expression level of 
IL-8, surprisingly, knocking down AP-1 transcription factor decreased the levels of IL-8 by 
42.1  ±  8.4% and 44.3  ±  3.2% at the levels of mRNA and protein, respectively (Fig. 22C, D). 
Knock down of all the transcription factors have affected the expression levels of CCL5. The 
C/EBPα knock down declined CCL5 production at mRNA and protein levels by 44.8 ± 4.1% 
and 30.1 ± 5.9%, respectively. Knockdown of C/EBPγ and AP-1 also decreased CCL5 
production at comparable level. Knockdown of C/EBPγ has decreased the expression of 
CCL5 by 48% and 32% at the level of mRNA and protein, respectively. Similarly, knockdown 
of AP-1 has decreased the expression of CCL5 by 45.3% at the level of mRNA and by 39.6% 
at the level of protein (Fig. 22E, F).  
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In all these experiments, the Scr siRNA showed slight decrease in CCL5 expression 
at RNA level but the change was statistically insignificant. Furthermore, the Scr siRNA did not 
show any effect on CCL5 expression at protein level suggesting specificity of the effects 
obtained by using C/EBPα, C/EBPγ and AP-1 siRNA. 
We have also confirmed the involvement of p38δ isoform in the activation of AP-1 by 
performing a western blot. We transfected SVG astrocytes with p38δ siRNA for 48 hours. 
These cells were either mock transfected or transfected with plasmid coding HIV-1 Tat. Whole 
cell lysates were prepared and p-c-jun levels were measured 6 hours post-transfection. HIV-
1 Tat mediated phosphorylation of c-jun has decreased by 30% upon knock down of p38δ 
(Fig. 23A). 
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Figure 22: HIV-1 Tat-mediated expression of cytokines/chemokines involves C/EBPα, C/EBPγ 
and activator protein-1 (AP-1) transcription factors: (A-F) Astrocytes were transfected with either 
scrambled or C/EBPα or C/EBPγ or AP-1 siRNA for a duration of 48 hours, followed by either mock 
transfection or transfection with HIV-1 Tat plasmid. (A, C, E) The expression levels of IL-6, IL-8 and 
CCL5 at mRNA were determined by real time RT-PCR at 6 hours post transfection. The values 
represented are normalized to their mock-transfected controls. (B, D, F) Multiplex cytokine assay was 
employed to measure the protein concentrations of IL-6, IL-8 and CCL5 in the cell culture supernatants 
at 48 hours post transfection. Each experiment was done at least in triplicate and each bar represents 
the ± SE of three individual experiments. Statistical analyses was performed by one-way ANOVA and ** 
denotes P-value of ≤ 0.01 
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Figure 23: Involvement of p38 mitogen activated-protein kinase (MAPK) 
delta isoform in the induction of cytokines/chemokines by HIV-1 Tat: (A) 
Astrocytes were transfected with p38δ siRNA for 48 hours, followed by 
transfection with HIV-1 Tat plasmid. The levels of p-c-jun were measured after 6 
hours of transfection. A representative Western blot is shown in the panel. Each 
experiment was done at least in triplicate and each bar represents the ± SE of 
three individual experiments. Statistical analyses was performed by one-way 
ANOVA and ** denotes p-value of ≤ 0.01. 
A
GAPDH
p-cjun
Mock   M+Scr M+p38δ Tat      T+Scr   T+p38δ
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
Mock Scr p38δ Tat T + Scr T + p38δ
p
-c
-j
u
n
 /
 G
A
P
D
H
* * 
65 
 
3.2.12 Role of JNK MAPK signaling molecule in the Induction of cytokines/chemokines 
by HIV-1 Tat 
In view of the IL-8 expression results obtained from knock down of AP-1, we wanted 
to explore the role of other upstream MAPKs that can lead to its activation. C-Jun N-terminal 
kinase (JNK) is another upstream signaling molecule that can activate AP-1. To determine 
the role of JNK in the up-regulation of IL-8 and other cytokines in astrocytes by HIV-1 Tat, we 
pretreated cells with a specific JNK inhibitor (SP600125) and measured the levels of 
cytokines/chemokines at 6 hours and 48 hours post transfection for mRNA and protein, 
respectively. The starting dose of the inhibitor was based on IC50 values from previous 
literature and was further optimized based on its effect on cell viability (data not shown) (Hsieh, 
Wang et al. 2010). Pretreatment of astrocytes with 10 μM concentration of SP600125 did not 
affect the expression levels of either IL-6 or CCL5 (Fig. 24A, C, E, F). However, pretreatment 
of astrocytes with SP600125 significantly affected the expression of IL-8. The expression of 
IL-8 was decreased by 42.4 ± 9.0% at the level of mRNA and by 58.3 ± 7.0% at the level of 
protein (Fig. 24C, D).  
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Figure 24: Involvement of C-Jun N-terminal kinase/mitogen-activated protein kinase (JNK 
MAPK) in HIV-1 Tat-mediated expression of IL-8. (A-F) SVG astrocytes were pretreated with JNK 
MAPK inhibitor (SP600125) for 1 hour prior to transfection. (A, C, E) The expression levels of IL-6, IL-
8 and CCL5 at mRNA level were determined at 6 hours post transfection by real time RT-PCR. The 
values represented are normalized to their mock- transfected controls. (B, D, E) IL-6, IL-8 and CCL5 
protein concentrations in the cell culture supernatants at 48 hours post transfection were determined 
by multiplex cytokine assay.  Each experiment was done at least in triplicate and each bar represents 
the ± SE of three individual experiments. Statistical analyses was performed by one-way ANOVA and 
** denotes P-value of ≤ 0.01. 
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To verify the activation of JNK, we measured the phosphorylation of JNK by western 
blot. Pretreatment with SP600125 decreased the HIV-1 Tat-mediated increase in 
phosphorylated JNK from 1.25 fold to 1 fold (Fig. 25A).  
  
Figure 25: Involvement of JNK MAPK in HIV-1 Tat mediated induction of IL-8: 
Astrocytes were either mock-transfected or transfected with HIV-1 Tat plasmid for 
duration of 6 hours and p-JNK and JNK were measured in whole cell extracts. A 
representative Western blot is shown in the panel. Each experiment was done at 
least in triplicate and each bar represents the ± SE of three individual experiments. 
Statistical analyses was performed by one-way ANOVA and ** denotes P-value 
of ≤ 0.01. 
A
GAPDH
p-JNK
T-JNK
Mock    M+SP    Tat     T+SP
0.6
0.8
1
1.2
1.4
Mock SP600125 Tat Tat + SP600125
p
-J
N
K
 /
 G
A
P
D
H
* * 
68 
 
Next, to determine whether JNK MAPK can lead to the activation of AP-1 transcription 
factor, we pretreated the astrocytes with SP600125 and measured the phosphorylation of c-
jun in whole cell lysates. As shown in figure 26 A, densitometric analysis of western blot shows 
that pretreatment with SP600125 decreased the levels of p-c-jun by 28.3 ± 3.3% compared to 
the HIV-1 Tat-transfected cells. To confirm the role of JNK MAPK in the activation of AP-1, 
we specifically knocked down JNK1 isoform using siRNA and measured the phosphorylated 
c-jun levels in whole cell lysates. Knock down of JNK1 decreased p-c-jun levels by 26.1 ± 5.2% 
compared to HIV-1 Tat-transfected cells (Fig. 26B).These results demonstrate that HIV-1 Tat 
mediated induction of IL-8 involves activation of JNK MAPK which in turn activates AP-1 
transcription factor.  
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Figure 26: HIV-1 Tat mediated activation of JNK MAPK activates AP-1 
transcription factor: (A) SVGA cells were pretreated with 10 µM 
concentration of SP 600125. The levels of p-c-jun were measured in whole 
cell extracts 6 hours after the transfection. (B) Astrocytes were transfected 
with JNK1 siRNA for 48 hours, followed by transfection with HIV-1 Tat 
plasmid. The levels of p-c-jun were measured after 6 hours of transfection. A 
representative Western blot is shown in the panels A and B. Each experiment 
was done at least in triplicate and each bar represents the ± SE of three 
individual experiments. Statistical analyses was performed by one-way 
ANOVA and ** denotes p-value of ≤ 0.01. 
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3.2.13 Role of ERK MAPK signaling molecule in the Induction of cytokines/chemokines 
by HIV-1 Tat 
 Extracellular signal–regulated kinase (ERK) is another upstream signaling molecule 
that can activate NF-κB and AP-1 transcription factors to induce the production of various pro-
inflammatory cytokines. To determine the role of ERK MAPK in the up-regulation of 
cytokines/chemokines in astrocytes induced by HIV-1 Tat, we pretreated cells with a specific 
ERK inhibitor (U0126) and measured the levels of cytokines/chemokines at the level of mRNA 
at 6 hours post transfection. The starting dose of the inhibitor was based on IC50 values from 
previous published literature and was further optimized based on its effect on cell viability 
(data not shown) (Song, Tanaka et al. 2004). Pretreatment of astrocytes with 10 μM 
concentration of U0126 did not affect the expression levels of either IL-6 or IL-8 or CCL5 (Fig. 
27A-C). Furthermore, U0126 has significantly increased the expression levels of IL-6 and IL-
8. Since, there was no decrease at the level of mRNA, we did not quantify the expression of 
these cytokines in the cell culture supernatants. These results indicate that HIV-1 Tat 
mediated induction of cytokines/chemokines does not involve ERK MAPK pathway. 
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Figure 27: HIV-1 Tat mediated induction of cytokines/chemokines does not involve ERK 
MAPK pathway: SVG astrocytes were pre-treated with ERK MAPK inhibitor, U0126 1 hour 
prior to the transfection. (A-C) The expression levels of IL-6, IL-8 and CCL5 were measured 6 
h after post-transfection with plasmid encoding HIV-1 Tat. The values are represented to their 
mock transfected controls. Each exoeriment was performed in triplicate and each bar 
represents the ± SE of three individual experiments. 
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3.2.14 Involvement of PI3K/Akt in HIV-Tat mediated up-regulation of 
cytokines/chemokines in astrocytes 
After determining the involvement of NF-κB and MAPK regulators in the up-regulation 
of IL-6, IL-8 and CCL5, we wanted to explore the role of further upstream signaling molecules 
that can activate NF-κB. The phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Akt 
pathway is a major upstream signaling mechanism that is involved in the regulation of 
cytokines by activation of NF-κB through IκB kinase (IKK)-mediated phosphorylation of IκBα 
(Kane, Shapiro et al. 1999). To ascertain the role of PI3K/Akt in the up-regulation of 
cytokines/chemokines by HIV-1 Tat, we initially employed an inhibitor approach wherein the 
cells were pretreated with LY294002, a reversible PI3K inhibitor. The starting dose of the 
inhibitor was based on IC50 values from previous literature and was further optimized based 
on its effect on cell viability (data not shown) (Fotheringham, Coalson et al. 2012). 
Pretreatment with 10 µM concentration of LY294002 decreased HIV-1 Tat mediated 
expression of IL-6 by 73.5 ± 2.6% and 81.3 ± 0.7% at the levels of mRNA and protein, 
respectively (Fig. 28A, B). The expression of IL-8 was also decreased by 43.3 ± 3.5% and 
55.1 ± 1.9% at mRNA and protein levels, respectively (Fig. 22C, D). Furthermore, 
pretreatment with LY294002 decreased CCL5 expression by 46.2 ± 4.3% at mRNA and 53.2 
± 7.44 at protein level (Fig. 28E, F). These results suggest that HIV-1 Tat mediated induction 
of IL-6, IL-8 and CCL5 involve PI3K/Akt pathway. 
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Figure 28: HIV-1 Tat-mediated expression of IL-6 and IL-8 involves PI3K/Akt pathway. (A-
F) Astrocytes were pretreated with a specific PI3K inhibitor (LY294002) for 1 hour prior to transfection. 
(A, C, E) The expression levels of IL-6, IL-8 and CCL5 at the level of mRNA were determined at 6 
hours post transfection by real time RT-PCR. The values represented are normalized to their mock-
transfected controls. (B, D, F) IL-6, IL-8 and CCL5 protein concentrations in the cell culture 
supernatants at 48 hours post transfection were determined by multiplex cytokine assay. Each 
experiment was done at least in triplicate and each bar represents the ± SE of three individual 
experiments. Statistical analyses was performed by one-way ANOVA and ** denotes P-value of ≤ 0.01 
and * denotes P-value of ≤ 0.05. 
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Activation of PI3k leads to the activation of downstream signaling molecule, Protein 
kinase B (Akt). Results with LY294002 indicate that PI3K/Akt pathway might be involved in 
HIV-1 Tat mediated induction of cytokines/chemokines. The involvement of PI3K/Akt was 
further confirmed by measuring the phosphorylation of Akt. The cells were mock transfected 
or HIV-1 Tat transfected and whole cell lysates were prepared 6 h post-transfection. The 
results show that HIV-1 Tat-mediated increase in phosphorylated Akt levels were decreased 
by pretreatment with LY294002 (Fig. 29A). HIV-1 Tat mediated 1.3 fold increase in Akt 
activation was completely abrogated by pre-treatment with LY294002. Activation of NF-κB by 
PI3K pathway was determined by measuring the translocation of p65 upon pretreatment with 
LY294002. Compared to HIV-1 Tat transfected cells, pretreatment with LY294002 decreased 
the translocation of p65 by 29.9 ± 5.9% (Fig. 30A). 
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Figure 29: HIV-1 Tat mediates activation of PI3K/Akt pathway: (A) 
Astrocytes were either mock-transfected or transfected with HIV-1 Tat plasmid 
for duration of 6 hours and p-Akt levels were measured in whole cell 
extracts. Experiment was done at least in triplicate and each bar represents 
the ± SE of three individual experiments. Statistical analyses was performed 
by one-way ANOVA and ** denotes p-value of ≤ 0.01. 
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Figure 30: HIV-1 Tat-mediated expression of cytokines involves PI3K/Akt 
and NF-κB pathway: (A) Astrocytes were transfected for a duration of 6 hours 
and translocation of p65 was measured. Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and LaminB were used as internal loading controls for 
cytoplasmic and nuclear protein fractions, respectively. A representative Western 
blot is shown in figure. Experiment was done at least in triplicate and each bar 
represents the ± SE of three individual experiments. Statistical analyses was 
performed by one-way ANOVA and ** denotes p-value of ≤ 0.01. 
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Akt is the effector downstream signaling molecule that is activated by upstream PI3K. 
To verify the involvement of PI3K/Akt pathway in the up-regulation of HIV-1 Tat mediated 
cytokines/chemokines, we have used siRNA against Akt. Akt exists in three different isoforms, 
(Akt1/Akt2/Akt3). The efficiency of gene knock down was verified previously. Individual knock 
down of all the isoforms decreased the expression levels of IL-6 and IL-8 by 35% and 30%, 
respectively at the levels of mRNA (Fig. 31A, C). Similar results were obtained at the protein 
level, where the decrease for IL-6 and IL-8 was found to be 35% and 28%, respectively (Fig. 
31B, D).  The knockdown of Akt2 and Akt3 but not Akt1 reduced the expression of CCL5 by 
34.05 ± 7.7% and 42.8 % ± 6.3% at the level of mRNA and by 29.25 ± 2.86% and 46.4 ± 
3.03% at protein levels (Fig. 31E, F). The results with inhibitor and siRNA demonstrate that 
HIV-1 Tat mediated induction of cytokines/chemokines involve activation of NF-κB through 
PI3K/Akt pathway. 
In conclusion, results indicate that HIV-1 Tat mediates the up-regulation of IL-6, IL-8 
and CCL5 in astrocytes involving different upstream signaling molecules and transcription 
factors (Fig. 32-34). 
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Figure 31: HIV-1 Tat-mediated expression of IL-6, IL-8 and CCL5 involves PI3K/Akt 
pathway: (A-F) Astrocytes were transfected with either scrambled or Akt1 or Akt2 or Akt3 siRNA 
for a duration of 48 hours, followed by either mock transfection or transfection with HIV-1 Tat 
plasmid. (A, C, E) The levels of IL-6 and IL-8 at mRNA level were determined by real time RT-
PCR at 6 hours post transfection. (B, D, F) The protein concentrations of IL-6 and IL-8 in cell 
culture supernatants at 48 hours post transfection were determined by multiplex cytokine assay. 
Each experiment was done at least in triplicate and each bar represents the ± SE of three 
individual experiments. Statistical analyses was performed by one-way ANOVA and ** 
denotes P-value of ≤ 0.01 and * denotes p-value of ≤ 0.05. 
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Figure 32: Schematic of signaling pathways involved in HIV-1 Tat-mediated up-regulation of IL-
6 in astrocytes. The major signaling pathways involved in HIV-1 Tat-mediated up-regulation of IL-6 are 
PI3K/Akt and p38 MAPK which lead to the activation of NF-κB and AP-1 (solid line). The siRNAs used 
to target various isoforms are indicated by a green color whereas drug targets are indicated by a blue 
color. The involvement and absence of a particular isoform or a signaling molecule is indicated by a 
dark color and a pale color, respectively. Specific inhibitors used for targeting signaling molecules are 
indicated by a red color. 
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Figure 33: Schematic of signaling pathways involved in HIV-1 Tat-mediated up-regulation of IL-
8 in astrocytes: Induction of IL-8 by HIV-1 Tat involves PI3K/Akt, p38 and C-Jun N-terminal 
kinase/mitogen activated-protein kinase (JNK MAPK) signaling pathways, leading to the activation of 
NF-κB and AP-1 transcription factors (broken line). The siRNAs used to target various isoforms are 
indicated by a green color whereas drug targets are indicated by a blue color. The involvement and 
absence of a particular isoform or a signaling molecule is indicated by a dark color and a pale color, 
respectively. Specific inhibitors used for targeting signaling molecules are indicated by a red color. 
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Figure 34: Schematic representation of the signaling pathways involved in HIV-1 Tat mediated 
up-regulation of CCL5 in astrocytes: The induction of CCL5 by HIV-1 Tat involved JAK/PI3K/Akt and 
p38 MAP kinase pathways. These signaling pathways differentially regulated the induction of CCL5 by 
activating various transcription factors, including NF-κB, C/EBPα, C/EBPγ and AP-1. The target 
molecules of siRNA are indicated in green color and the involvement of a specific isoform is shown in 
brighter color and the absence is shown in pale color. The specific inhibitors for their respective targets 
are shown in red. 
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3.3 Discussion 
HIV-1 associated neurological deficits range from minor cognitive motor disorders 
(MCMD) to a more severe form of dementia referred to as HAD. Several mechanisms, 
including the dysregulation of cytokine profile and infiltration of various inflammatory cells and 
oxidative stress have been proposed for the development of HAND in patients infected with 
HIV-1 (Rappaport, Joseph et al. 1999, Li, Galey et al. 2005). Elevated levels of pro-
inflammatory cytokines including IL-6, IL-8, and IFN-γ have been found in the various regions 
of the brain in HIV infected people (Griffin, McArthur et al. 1991, Mastroianni, Paoletti et al. 
1992, Mamik and Ghorpade 2012). Further, increased CCL5 has not only been detected in 
the CSF, but it has been directly correlated with viral load in CSF and MCMD (Kelder, 
McArthur et al. 1998, Letendre, Lanier et al. 1999). Moreover, elevated levels of IL-6 and IL-
8 have been shown to play important roles in many inflammatory responses such as 
recruitment of leukocytes, accumulation of neutrophils and production of acute phase proteins 
(Baggiolini and Clark-Lewis 1992, Gabay 2006). Viral proteins, especially HIV-1 Tat and 
gp120, have been implicated in this phenomenon. Additionally, HIV-1 proteins (gp120 and 
Tat) have been shown to increase the cytokine/chemokines expression in the cells of CNS 
origin (El-Hage, Gurwell et al. 2005, Shah, Verma et al. 2011). However, very little is known 
about the molecular mechanisms behind the up regulation of these cytokines/chemokines. In 
the present study, we sought to dissect the molecular mechanisms behind the up regulation 
of cytokines/chemokines by HIV-1 Tat in SVG astrocytes. The astrocytes were transfected 
with an expression plasmid encoding HIV-1 Tat and the expression levels of 
cytokines/chemokines were determined at various time points. The results showed a time 
dependent increase in the expression of IL-6, IL-8 and CCL5 at the level of mRNA and protein. 
These results are in agreement with the previous literature showing the over expression of IL-
6, IL-8 and CCL5 induced by HIV-1 Tat (Kutsch, Oh et al. 2000, Ju, Song et al. 2009). 
However, the secretion of IL-6 was different compared to that shown in the previous studies 
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(Ju, Song et al. 2009). This can be attributed to the difference in the type of cell line used 
(CRT-MG vs SVG astrocytes) and also different methods of HIV-1 Tat exposure (protein 
treatment vs transfection). However, the expression of IL-8 at protein level was consistent to 
that obtained by Kutch et al, where they demonstrated increased IL-8 protein expression with 
HIV-1 Tat protein treatment in primary astrocytes (Kutsch, Oh et al. 2000). The role of CCL5 
in the context of HIV is uncertain. CCL5 interacts with CCR5 receptor to inhibit the replication 
of various macrophage-tropic strains of HIV-1 at a concentration of 50-250 ng/ml (Arenzana-
Seisdedos, Virelizier et al. 1996, Trkola, Paxton et al. 1998). On the other hand, CCL5 at 1-
10 μg/ml concentration increased the HIV-1 infectivity by activating p44/p42 MAPK (Gordon, 
Muesing et al. 1999, Chang, Gordon et al. 2002). CCL5 has also been shown to exhibit 
neuroprotective properties by decreasing the neuronal apoptosis induced by gp120 (Kaul and 
Lipton 1999, Catani, Corasaniti et al. 2000). However these concentrations are very high when 
compared to the concentrations that have been reported in the CSF of HIV infected patients 
suffering from dementia and opportunistic infections where CCL5 concentration have been 
reported to be in the range of 50-200 pg/ml (Kelder, McArthur et al. 1998, Christo, Vilela Mde 
et al. 2009). In another case of Neisseria meningitides/meningioma cell culture system, 5-10 
ng/ml concentrations of CCL5 were shown to play a role in inflammatory responses (Fowler, 
Yin et al. 2006). These studies suggest that, a lower concentration of CCL5 perhaps causes 
inflammation whereas higher concentration might be involved in protective effect. In our study, 
we achieved the peak concentration of CCL5 in the range of 2-4 ng/ml, which would be 
expected to lead into pro-inflammatory response. Our results with immunocytochemistry also 
confirm the elevated presence of IL-6, IL-8 and CCL5 in HIV-1 Tat transfected astrocytes. 
NF-κB is a major transcription factor involved in regulating the expression of many 
cytokines and chemokines. It binds to the promoter region of many genes, including IL-6 and 
IL-8 to regulate their expression (Matsusaka, Fujikawa et al. 1993). Previous studies have 
shown increased binding and activation of NF-κB by HIV-1 Tat in various cells, including 
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astrocytes and microglia (Conant, Ma et al. 1996, Nicolini, Ajmone-Cat et al. 2001). Recent 
study by Fiume and coworkers has shown that HIV-1 Tat increased the binding of p65 DNA 
and also its transcriptional activity (Fiume, Vecchio et al. 2012). In agreement with these 
reports, we have also observed a time dependent increase in the translocation of p65 into the 
nucleus by HIV-1 Tat in SVG astrocytes. Next, we demonstrated the involvement of NF-κB in 
the up regulation of IL-6 and IL-8 by pretreating the astrocytes with BAY 11-7082, a specific 
inhibitor of IκB kinase 2 (IKK2). In order to determine involvement of NF-κB, we used SC514, 
a specific inhibitor of IκB kinase 2 (IKK2). SC514 prevents the degradation of IκBα and thereby 
prevents the translocation of NF-κB (Kishore, Sommers et al. 2003). In accordance with the 
previous reports, we also observed SC514 mediated reduction of CCL5 expression 
suggesting a role for NF-κB. 
To confirm the data with the pharmacological inhibitor, we have employed the siRNA 
approach. NF-κB is comprised of different subunits of which p65 and p50 are important in 
regulating the expression of several cytokines/chemokines. The transcriptional activity is 
mainly attributed to p65 subunit of NF-κB (Vallabhapurapu and Karin 2009). The two subunits 
were knocked down individually by using siRNA and expression of IL-6, IL-8 and CCL5 were 
measured. Knock down of p65 but not p50 has decreased the expression levels of both IL-6 
and IL-8 in astrocytes by HIV-1 Tat. This suggests the possibility that p65 homodimers are 
more important in regulating the expression of IL-6 and IL-8 from astrocytes by HIV-1 Tat. 
This is in agreement with the findings by Georganas et al showing p65 homodimers but not 
p50 homodimers are important in regulating the expression of both IL-6 and IL-8 in rheumatoid 
arthritis fibroblast like synoviocytes (Georganas, Liu et al. 2000). Surprisingly, knock down of 
p50 has increased the expression levels of IL-8 at the level of mRNA and protein. This can be 
attributed to the role of p50 homodimer as transcriptional repressor (Plaksin, Baeuerle et al. 
1993). (Plaksin, Baeuerle et al. 1993) 
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Therefore, it seems that HIV-1 Tat does not use p50 homodimer for up regulating the 
expression of IL-8. However, further investigation needs to be done to determine the role of 
p50 homodimer on the expression of IL-8. However, knock down of p50 and p65 has 
significantly decreased the expression levels of CCL5 at mRNA and protein, confirming our 
results with the chemical antagonist. These results indicate that p50 and p65 heterodimer is 
involved in HIV-1 Tat mediated expression of CCL5 in astrocytes. Overall, our results indicate 
that HIV-1 Tat differentially affects various NF-κB transcription factors to regulate the 
expression of IL-6, IL-8 and CCL5.  
After determining the role of NF-κB, we sought to look at the role of upstream signaling 
molecules that can lead to up regulation of IL-6, IL-8 and CCL5 by HIV-1 Tat. MAPKs are 
important upstream signaling molecules that can result in the activation of many cytokines 
mediated through NF-κB. Particularly, p38 MAPK, belonging to the family of serine/threonine 
protein kinases has been shown to be involved in the up regulation of many 
cytokines/chemokines (Lee, Laydon et al. 1994).  The involvement of p38 MAPK in the up 
regulation of IL-6, IL-8 and CCL5 by HIV-1 Tat was determined by pretreating the astrocytes 
with SB203580, a specific inhibitor of p38 MAPK. SB203580 significantly decreased the 
expression levels of IL-6 and IL-8, but did not affect the expression of CCL5. p38 MAPK exists 
in four different isoforms (α/β/γ/δ), of which SB203580 inhibits p38α and p38β isoforms (Lee, 
Kassis et al. 1999). Both these isoforms of p38 
 lead to the activation of NF-κB (Kumar, Behera et al. 2010). To verify the involvement 
of NF-κB activation (p38α and p38β isoforms) and role of other two isoforms (p38γ and p38δ) 
in the up regulation of IL-6, IL-8 and CCL5 by HIV-1 Tat, we have individually knocked down 
all the isoforms using siRNA. Consistent with the results of SB203580, knock down of p38β 
but not p38α has partially decreased the expression levels of IL-6 and IL-8. The decrease in 
the translocation of p65 into the nucleus with SB203580 pretreatment demonstrated the 
connection between p38 MAPK and NF-κB. Specifically decrease in the translocation of p65 
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upon knock down p38β shows that this isoform is more important for the activation of NF-κB 
by HIV-Tat. As knock down of p38δ partially reduced the expression levels of IL-6 and CCL5 
and it does not lead to the activation of NF-κB, we wanted to determine the role of various 
other transcription factors that can be activated by it. p38δ activation is associated with 
increased activation of various transcription factors, including AP-1, C/EBPα and C/EBPγ 
(Efimova, Broome et al. 2003). Our results demonstrated that knock down of c-jun (important 
component of AP-1) but not C/EBPα and C/EBPγ has partially decreased the expression 
levels of IL-6. Our results showed reduction of CCL5 levels after knocking down AP-1, C/EBPα 
and C/EBPγ which clearly suggests the involvement of these transcription factors in the 
regulation of HIV-1 Tat-mediated CCL5 expression. The western blot showing a decrease in 
the phosphorylation of c-jun by HIV-1 Tat upon knock down of p38δ isoform demonstrates 
that this isoform is important in HIV-1 Tat mediated expression of IL-6 and CCL5.  
As p38δ knock down did not alter the expression levels of IL-8 mediated by HIV-1 Tat, 
we were surprised to see the decreased expression levels of IL-8 by HIV-1 Tat upon knock 
down of AP-1. Then we tested the possibility of other upstream signaling molecules that can 
activate c-jun to induce the expression levels of IL-8 by HIV-1 Tat. Several previous studies 
have shown the role of JNK MAPK in the activation of c-jun (Papachristou, Batistatou et al. 
2003). JNK belongs to the family of MAPK and is involved in the activation of transcription 
factors in response to various stimuli. We demonstrated the role of JNK MAPK in the 
expression of IL-8 by HIV-1 Tat by pretreatment with SP600125, a specific inhibitor of JNK. It 
acts by competing with ATP to inhibit the phosphorylation of c-jun. Pretreatment of astrocytes 
with SP600125 and also siRNA against JNK has decreased the phosphorylation levels of c-
jun by HIV-1 Tat. These results unequivocally demonstrate that JNK MAPK is important in the 
expression of IL-8 mediated by HIV-1 Tat. JNK did not affect the expression levels of IL-6 and 
CCL5. 
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PI3K/Akt is a major signaling molecule that can modulate the activation of NF-κB by 
promoting the phosphorylation of IκBα (Heck, Lezoualc'h et al. 1999). Several previous 
studies have indicated the role for HIV-1 and HIV-1 Tat in the activation of PI3K/Akt pathway 
in macrophages (Chugh, Bradel-Tretheway et al. 2008, Lucas, Kim et al. 2010). In our study, 
pretreatment of SVG astrocytes with reversible PI3K inhibitor, LY294002, decreased HIV-1 
Tat mediated increase in the phosphorylation of PI3K. It also partially decreased HIV-1 Tat 
mediated increase in IL-6, IL-8 and CCL5. Akt or Protein Kinase B is a downstream signaling 
molecule of PI3K. It belongs to the family of serine/threonine protein kinases and is known to 
exist in three different isoforms (Akt1/PKBα, Akt2/PKBβ, Akt3/PKBγ). All three isoforms of Akt 
are present in the brain and differ in their phosphorylation sites (Easton, Cho et al. 2005). Akt3 
is predominantly important in the brain since it contributes for more than 50% of all the Akt 
isoforms found in the brain. In our study, individual knock down of all the isoforms by siRNA 
has decreased the expression levels of IL-6 and IL-8 mediated by HIV-1 Tat. These findings 
indicate the importance of all the isoforms in the expression of IL-6 and IL-8 mediated by HIV-
1 Tat. In our study, siRNA against Akt2 and Akt3, but not Akt1 showed substantial reduction 
in the expression of CCL5. These findings suggest that perhaps the brain specific isoforms of 
Akt; i.e. Akt2 and Akt3, play an important role in the expression of CCL5, via activation of NF-
κB, which serves as one of the several transcription factor in this process.  
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CHAPTER 4 
HIV-1 TAT AND METHAMPHETAMINE MEDIATED EXPRESSION OF IL-6 INVOLVES 
NF-Κb AND PI3K/Akt PATHWAYS 
4.1 Introduction 
More than 30% of the people infected with HIV-1 suffer from a range of neurological 
disorders, collectively referred to as HIV associated neurocognitive disorders (HAND) 
(Sacktor, Skolasky et al. 2016). HIV-1 crosses the blood brain barrier soon after infection 
through the infected monocytes and replicates inside microglia and astrocytes (Gonzalez-
Scarano and Martin-Garcia 2005). Several mechanisms have been implicated in the 
development of HAND, including ongoing viral replication and neurotoxicity mediated by 
virotoxins like gp120 and HIV-1 Tat. Soluble Tat has been shown to be present in HIV-1 
infected individuals even after the initiation of combined antiretroviral therapy (cART) 
(Mediouni, Darque et al. 2012).  
HIV-1 Transactivator of transcription (HIV-1 Tat) is early protein expressed by the 
proviral DNA and greatly enhances the viral replication (Dayton, Sodroski et al. 1986). Tat is 
actively secreted by the infected cells and affects various signaling molecules of bystander 
uninfected cells through the interaction of their surface receptors or by internalizing into the 
cells (Tyagi, Rusnati et al. 2001). Intraventricular injection of HIV-1 Tat has been shown to be 
neurotoxic to mice (Jones, Olafson et al. 1998).  Neurotoxicity mediated by HIV-1 Tat can 
occur through direct interaction with neurons and indirect actions on surrounding cells to 
promote the release of soluble mediators. These mediators include production of various pro-
inflammatory cytokines, reactive oxygen species, quinolinic acid and glutamate (Gupta, Knight 
et al. 2010, Li, Yim et al. 2010, Kim, Smith et al. 2015). Furthermore, HIV-1 Tat interacts with 
neurons to promote neuronal apoptosis through various mechanisms, including activation of 
NMDA receptors, glutamate excitotoxicity, increase in the levels of intracellular calcium 
concentration, alteration of mitochondria potential and activation of cytochrome c and 
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endonuclease G pathways (Singh, Goody et al. 2004, Zhu, Yao et al. 2009, Lecoeur, Borgne-
Sanchez et al. 2012, Krogh, Wydeven et al. 2014). 
Drugs of abuse are an important comorbid factor in individuals infected with HIV-1. 
More than 50% of the people with HIV-1 use and abuse one of the illicit drugs. 
Methamphetamine is a psychostimulant and is one of the most commonly abused illicit drugs 
among HIV infected individuals in the United States. It promotes neurotoxicity by primarily 
affecting dopaminergic neurons and also by affecting the levels of various neurotransmitters 
at the synapse (Larsen, Fon et al. 2002, Yamamoto, Moszczynska et al. 2010, Yu, Zhu et al. 
2015). Moreover, methamphetamine has been shown to affect the integrity of blood brain 
barrier by up-regulating the expression of various pro-inflammatory cytokines including IL-6, 
IL-8, TNF-α and inducing oxidative stress (Ramirez, Potula et al. 2009, Shah, Silverstein et 
al. 2012, Wang, Qian et al. 2014, Coelho-Santos, Leitao et al. 2015, Wongprayoon and 
Govitrapong 2015). Furthermore, methamphetamine exacerbates neurocognitive 
impairments seen in HIV infected individuals (Rippeth, Heaton et al. 2004, Carey, Woods et 
al. 2006). Several recent studies have indicated the role of HIV-1 Tat in augmentation of 
neurotoxicity mediated my methamphetamine. However, there are no studies indicating the 
combined role of methamphetamine and HIV-1 Tat in the up-regulation of cytokines from 
astrocytes, an important contributor of neurotoxicity. 
In previous studies, we have shown the up-regulation of cytokines by HIV-1 and 
methamphetamine from astrocytes involving PI3K/Akt and NF-κB pathways. The present 
study was undertaken to determine the combined effect of HIV-1 Tat and methamphetamine 
in the up-regulation of cytokines from astrocytes. We also sought to determine the role of 
PI3K/Akt and NF-κB signaling pathway in HIV-1 Tat and methamphetamine mediated up-
regulation of cytokines. We chose SVGA astrocytic cell line and primary astrocytes to 
investigate our hypothesis.  
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4.2 Results 
4.2.1 Methamphetamine exacerbates the production of IL-6 mediated by HIV-1 Tat in 
astrocytes 
In our earlier studies, we have demonstrated that HIV-1 Tat or methamphetamine 
treatment alone induces the production of IL-6 and IL-8 from astrocytes (Shah, Silverstein et 
al. 2012). Furthermore, several studies have shown interaction of methaphetamine with HIV-
1 Tat to potentiate its effect by several mechanisms, including increased oxidative stress 
(Flora, Lee et al. 2003), activation of matrix metalloproteinases (Conant, St Hillaire et al. 
2004), alteration of dopaminergic neurons function (Maragos, Young et al. 2002), and 
promoting neuronal apoptosis (Qi, Gang et al. 2011). Along similar lines, we hypothesized 
that methamphetamine augments HIV-1 Tat mediated production of cytokines from 
astrocytes. To test our hypothesis, we treated SVGA cells with 500 µM methamphetamine for 
three days and transfected them with or without plasmid coding HIV-1 Tat. We tested the 
mRNA expression levels of IL-6 and IL-8 at 6 hour post-transfection as we previously have 
demonstrated their induction with methaphetamine and HIV-1 Tat alone. We found that HIV-
1 Tat and methamphetamine combination treatment has significantly increased the 
expression levels of IL-6 compared to treatment with either Tat or methamphetamine alone 
(Fig 35A). Even though, there was induction of IL-8 by HIV-1 Tat and methamphetamine 
alone, combination treatment has significantly decreased its expression levels at both mRNA 
and protein levels (Fig 35B). 
Therefore, we have performed a time kinetics to determine the expression of IL-6 at 
mRNA and protein levels. We found that the expression levels of IL-6 for mRNA levels have 
started to increase from 3 h, peaked at 6 h (24.6 ± 1.1 fold for Tat, 6.9 ± 0.8 fold for 
Methamphetamine and 38.8 ± 1.4 fold for combination treatment) and started to decrease 
until the observation period (until 24 h) (Fig 36A). We also determined the protein level of IL-
6 at 6 h, 12 h, 24 h and 48 h post-transfection by bioplex assay. The expression of IL-6 started 
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to increase from 6 h until indicated time point (48 h). The peak increase in the expression of 
IL-6 at 48 h was found to be 9.36 ± 0.36 ng/ml for Tat treatment, 3.27 ± 0.11 ng/ml for 
methamphetamine treatment and 20.94 ± 1.63 ng/ml for combination treatment (Fig 36B). We 
have also confirmed our results using primary astrocytes isolated from aborted human fetus. 
We quantified IL-6 mRNA expression 2 h after treating primary astrocytes with 200 ng/ml of 
recombinant Tat protein and/or 500 µM methamphetamine. Combination treatment has 
increased the expression of IL-6 by 28.0 ± 5.1 fold compared to either HIV-1 Tat (8.9 ± 2.7 
fold) or methamphetamine (2.5 ± 0.1 fold) treatments alone (Fig 36C).  
   
Figure 35: Methamphetamine exacerbates HIV-1 Tat mediated induction of IL-6 but not IL-8 
in astrocytes: SVG astrocytes were treated with 500 µM methamphetamine for 3 days before 
transfecting them with HIV-1 Tat. Expression levels of IL-6 and IL-8 were determined 6 hours post 
transfection by using real time RT-PCR. Each experiment was performed in triplicate and SE 
represents mean of three independent experiments. Statistical significance was calculated using 
one-way ANOVA with Tukey’s post-hoc analysis and p-value ≤ 0.05 is considered as statistically 
significant. 
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Figure 36: Methamphetamine exacerbates HIV-1 Tat mediated induction of IL-6 at RNA and 
protein levels in astrocytes: SVG astrocytes were treated with 500 µM methamphetamine for 3 
days before transfecting them with HIV-1 Tat. (A) Cells were harvested at 3, 6, 12 and 24 hours and 
expression levels of IL-6 mRNA were determined using real time RT-PCR. (B) Cell culture 
supernatants were collected at 6, 12, 24 and 48 hours post-transfection and IL-6 protein levels were 
determined using bioplex assay. (C) Primary human astrocytes from two independent donors were 
treated with 200 ng/ml of HIV-1 Tat protein and 500 µM of methamphetamine and harvested after 
2 h to determine IL-6 mRNA using real time RT-PCR. Each experiment was performed in triplicate 
and SE represents mean of three independent experiments. Statistical significance was calculated 
using one-way ANOVA with Tukey’s post-hoc analysis and p-value ≤ 0.05 is considered as 
statistically significant. 
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4.2.2 Methamphetamine and HIV-1 Tat mediated induction of IL-6 involves NF-κB 
pathway 
We and several other groups have previously shown the activation of NF-κB by HIV-1 
Tat and methamphetamine in astrocytes. Furthermore, we have previously shown that NF-κB 
is involved in HIV-1 Tat or methamphetamine mediated production of IL-6. In order to 
determine the involvement of NF-κB in the interaction of methamphetamine and HIV-1 Tat 
mediated production of IL-6, we measured the expression p-IκBα in whole cell lysates and 
p65 translocation in nuclear and cytoplasmic extracts. Phosphorylation of IκBα was increased 
by HIV-1 Tat and methamphetamine treatments either in combination or alone. Combination 
treatment increased the expression of p-IκBα by 47.6 ± 12 % compared to mock transfected 
cells (Fig 37A). As expected, expression of p- IκBα also was also increased to a similar extent 
by individual treatment of HIV-1 Tat or methamphetamine. We have previously shown the 
translocation of NF-κB subunits into nucleus upon treatment with HIV-1 Tat and 
methamphetamine. In order to determine the involvement of NF-κB, we measured the 
translocation of p65 subunit upon HIV-1 Tat transfection and/or methamphetamine treatment 
for 6 hours and there was significant increase in all the treatment groups. Even though, there 
was slight increase in the translocation of p65 with the combination treatment compared to 
HIV-1 Tat transfection (82.9 ± 17.8% vs 57.7 ± 2.1%), statistical significance was not achieved 
(Fig 37B). Results from p- IκBα and p65 translocation experiments indicate that NF-κB is 
involved in HIV-1 Tat and methamphetamine mediated production of IL-6. To further confirm 
our findings, we have pretreated SVGA cells with 10 µM BAY 11-7082 1 hour prior to treatment 
with methamphetamine and/or transfection with HIV-1 Tat and harvested at 6 h and 48 h post-
transfection for the quantification of IL-6 at mRNA and protein levels. Results show that BAY 
11-7082 significantly decreased HIV-1 Tat and/or methamphetamine mediated production of 
IL-6 at mRNA and protein levels (Fig 38A, B).  
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Figure 37: Methamphetamine and HIV-1 Tat induces NF-κB activation in astrocytes: SVG 
astrocytes were treated with 500 µM methamphetamine for 3 days before transfecting them with 
HIV-1 Tat. (A) Cells were harvested after 3 hours post-transfection and expression of p-IκBα was 
determined by western blot. (B) Cells were harvested after 6 hours post-transfection to separate 
nuclear and cytoplasmic fractions and measure p65 translocation into nucleus. GAPDH was used 
as a loading control for whole cell lysates and cytoplasmic fraction and LaminB was used as loading 
control for nuclear fraction.Each experiment was performed in triplicate and SE represents mean of 
three independent experiments. Statistical significance was calculated using one-way ANOVA with 
Tukey’s post-hoc analysis and p-value ≤ 0.05 is considered as statistically significant. 
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4.2.3 Involvement of PI3K/Akt pathway in HIV-1 Tat and methamphetamine mediated 
potentiation of IL-6 
We have investigated the role of PI3K/Akt pathway in HIV-1 Tat and 
methamphetamine mediated production of IL-6 in astrocytes. PI3K/Akt is an important 
upstream signaling pathway that is involved in the activation of NF-κB and also has been 
shown to involve in HIV-1 Tat or methamphetamine mediated production of cytokines from 
astrocytes. In order to demonstrate the involvement of PI3K/Akt pathway, SVGA cells were 
transfected with HIV-1 Tat and/or methaphetamine for 3 hours and p-Akt levels were 
measured in whole cell lysates. There was significant increase in the expression of 
phosphorylated Akt by all the treatment groups (approximately by 50-100%) (Fig 39A). Similar 
to p-IκBα expression levels, there was no significant difference in the expression levels of p-
Akt by different treatment groups. To further confirm the involvement of PI3K/Akt pathway, 
SVGA cells were pretreated with 10 µM LY294002, a specific PI3K inhibitor and the 
Figure 38: NF-κB is involved in the induction of IL-6 by methamphetamine and HIV-1 Tat: 
SVG astrocytes were treated with 500 µM of MA for 72 hours (3 days). The cells were seeded at 
2.75 x 105 cells/well in 12-well plates. The cells were transfected with 0.3 µg of plasmid expressing 
HIV-1 Tat. Cells were pre-treated with specific inhibitors for NF-κB pathway (BAY 11-7082) 1 h prior 
to the addition of MA and/or HIV-1 Tat. The cells were harvested 6 hours and 48 hours after post-
transfection for the determination of mRNA (A) and protein (B) levels, respectively. Each bar shows 
the mean ± SE of three independent experiments performed in triplicate. The p-values ≤ 0.01 were 
considered statistically significant when calculated using one-way ANOVA. 
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expression levels of IL-6 was measured at 6 h post-transfection for mRNA and 48 h post-
transfection for protein (Fig 40A, B). Together, these results indicate that HIV-1 Tat mediated 
induction of IL-6 was potentiated by methamphetamine and involves P3K/Akt pathway. 
Overall, our results indicate that methamphetamine potentiates the induction of IL-6 at mRNA 
and protein levels by HIV-1 Tat from astrocytes. Furthermore, potentiation of IL-6 occurs 
through the involvement of PI3K/Akt and NF-κB pathways.  
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Figure 39: Methamphetamine and HIV-1 Tat induces PI3K/Akt activation in astrocytes: SVG 
astrocytes were treated with 500 µM methamphetamine for 3 days before transfecting them with 
HIV-1 Tat. (A) Cells were harvested after 3 hours post-transfection and expression of p-Akt was 
determined by western blot. GAPDH was used as a loading control to normalize the expression. 
Each experiment was performed in triplicate and SE represents mean of three independent 
experiments. Statistical significance was calculated using one-way ANOVA with Tukey’s post-hoc 
analysis and p-value ≤ 0.05 is considered as statistically significant. 
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Figure 40: PI3K/Akt pathway is involved in the induction of IL-6 by methamphetamine and 
HIV-1 Tat: SVG astrocytes were treated with 500 µM of MA for 72 hours (3 days). The cells were 
seeded at 2.75 x 105 cells/well in 12-well plates. The cells were transfected with 0.3 µg of plasmid 
expressing HIV-1 Tat. Cells were pre-treated with specific inhibitors for PI3K pathway (LY 294002) 
1 h prior to the addition of MA and/or HIV-1 Tat. The cells were harvested 6 hours and 48 hours 
after post-transfection for the determination of mRNA (A) and protein (B) levels, respectively. Each 
bar shows the mean ± SE of three independent experiments performed in triplicate. The p-values ≤ 
0.01 were considered statistically significant when calculated using one-way ANOVA. 
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4.3 Discussion 
Cytokines and chemokines are crucial for the regulation of immune responses in the 
CNS. However, increased production of pro-inflammatory cytokines is associated with 
pathology in several disease states, including Alzheimer’s disease, Parkinson’s disease, 
meningitis and HAND (Nagatsu, Mogi et al. 2000, Hanisch, Prinz et al. 2001, Brosseron, 
Krauthausen et al. 2014, de Almeida, Rotta et al. 2016). Elevated levels of various pro-
inflammatory cytokines and chemokines often serve as biomarkers to correlate with the 
severity of HAND in individuals infected with HIV-1 (Yuan, Qiao et al. 2013, de Almeida, Rotta 
et al. 2016). One-third of the population infected with HIV-1 abuse one of the recreational 
drugs, including methamphetamine, cocaine and opioids and are associated with faster 
disease progression. Methamphetamine use in particular, promotes risky sexual behavior and 
increases the risk of acquiring HIV (Plankey, Ostrow et al. 2007). An earlier study, Rippeth et 
al have shown that HIV infected individuals who abuse methamphetamine exhibit a greater 
degree of neuropsychological impairment compared to individuals who abuse 
methamphetamine or infected with HIV (Rippeth, Heaton et al. 2004). Furthermore, several 
studies have shown that methamphetamine increases HIV replication and also increases 
brain viral load using in vitro and in vivo models (Liang, Wang et al. 2008, Nair, Saiyed et al. 
2009, Marcondes, Flynn et al. 2010). Methamphetamine has also been shown to promote the 
expression of various pro-inflammatory cytokines (Shah, Silverstein et al. 2012, Robson, 
Turner et al. 2013). Interaction of methamphetamine and Tat have shown to promote higher 
expression of cytokines and induce neurotoxicity (Theodore, Cass et al. 2006, Theodore, 
Cass et al. 2006).  
Therefore, we wanted to determine the underlying signaling mechanisms that are 
involved in methamphetamine and HIV-1 Tat mediated production of cytokines in astrocytes. 
We have shown that HIV-1 Tat and methamphetamine interact to induce higher expression 
of IL-6 from astrocytes at mRNA and protein levels. For the first time, we have shown that 
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HIV-1 Tat mediated induction of IL-6 in astrocytes is exacerbated by treatment with 
methamphetamine. We also confirmed our findings using primary human fetal astrocytes.  
NF-κB is a major transcriptional factor that is involved in the regulation of various 
cytokines (Lawrence 2009, Hoesel and Schmid 2013). We and several other groups have 
previously shown the involvement of NF-κB in the induction of cytokines by HIV-1 Tat or 
methamphetamine (Shah, Silverstein et al. 2012, Nookala and Kumar 2014). We therefore 
investigated the role of NF-κB as an overlapping mechanism in HIV-1 Tat and 
methamphetamine mediated production of IL-6. We have shown increased translocation of 
p65 and phosphorylation of IκBα upon treatment with HIV-1 Tat and methaphetamine. 
Furthermore, increased expression of IL-6 by methamphetamine and/or HIV-1 Tat treatment 
was decreased upon pre-treatment with BAY 11-7082, a specific NF-κB inhibitor. These 
results confirm the involvement of NF-κB in HIV-1 Tat mediated induction of IL-6 that is 
exacerbated by methamphetamine in astrocytes.  
PI3K is an upstream signaling pathway that is involved in the activation of NF-κB by 
inducing the phosphorylation of IκBα (Heck, Lezoualc'h et al. 1999). We and several other 
groups have previously shown the involvement of Pi3K in the induction of cytokines by HIV-1 
Tat or methamphetamine (Shah, Silverstein et al. 2012, Nookala and Kumar 2014). Our 
results with the use of LY294002, a specific PI3K inhibitor decreased HIV-1 Tat and 
methamphetamine mediated production of IL-6 in astrocytes.  
In conclusion, our results for the first time demonstrated exacerbated production of IL-
6 at mRNA and protein levels by combination treatment with methamphetamine and HIV-1 
Tat in astrocytes. Exacerbation of IL-6 is induced by overlapping mechanisms involving 
PI3K/Akt and NF-κB pathways. 
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CHAPTER 5 
EFFECT OF HIV-1 Tat AND METH ON COGNITION AND EXPRESSION OF VARIOUS 
SYNAPTIC GENES 
5.1 Introduction 
HIV-1 infection results in the development of wide range of neurocognitive disorders, 
together referred to as HIV-Associated Neurocognitive Disorders (HAND). Introduction of 
combination Anti-Retroviral Therapy (cART) has increased the life expectancy of people 
infected with HIV-1 and thereby, prevalence of HAND has increased over the past decade 
(Dore, McDonald et al. 2003). More than 50% of the people infected with HIV-1 develop some 
form of neurocognitive impairment (Heaton, Clifford et al. 2010). Higher degree of 
neurocognitive impairment interferes with the individual’s ability to perform day to day activities 
(Antinori, Arendt et al. 2007). The incidence and degree of neurocognitive impairments are 
higher among individuals abusing illicit drugs, especially methamphetamine (Boddiger 2005, 
Potula and Persidsky 2008). HIV-1 does not infect the neurons, but neuronal damage and 
toxicity is the major feature of HAND. This neuronal toxicity is explained by direct and indirect 
actions of released viral proteins (gp120, HIV-1 Tat, Nef, Vpr). Viral proteins can directly act 
on the neurons or indirectly promote the release of various soluble mediators from different 
brain cells or change the environment of brain to cause neurotoxicity. The neurocognitive 
impairments associated with HIV-1 infection produces correlates with changes in synaptic 
proteins and dendrites (Masliah, Heaton et al. 1997, Everall, Heaton et al. 1999).   
HIV-1 transactivator of transcription (HIV-1 Tat or Tat) is a viral protein that is released 
very early during the viral replication. It binds to the transactivation response element of the 
viral mRNA to promote transcriptional elongation (Cann, Rosenblatt et al. 1985). HIV-1 
infected individuals with dementia and encephalitis show elevated levels of Tat mRNA in their 
brain tissues (Del Valle, Croul et al. 2000, Hudson, Liu et al. 2000). Tat is released in active 
form from infected cells and uptaken by different brain cells and neurons by passive diffusion 
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or by interacting with various receptors (Liu, Jones et al. 2000, Tyagi, Rusnati et al. 2001, 
King, Eugenin et al. 2006). Tat is known to promote neurotoxicity by various mechanisms; 
including glutamate excitotoxicity (Haughey, Nath et al. 2001), NMDA mediated increase in 
intracellular calcium levels (Krogh, Lyddon et al. 2015), increase in reactive oxygen species 
and nitric oxide levels (Kim, Smith et al. 2015), increase in cytokines (Nookala and Kumar 
2014, Mediouni, Jablonski et al. 2015) and disruption of blood brain barrier (Huang, Chen et 
al. 2014). Tat alters the expression of various genes associated with synaptic plasticity, 
thereby preventing the consolidation of short term events into long term memory. 
Neuropathology that is seen in doxycycline inducible Tat transgenic mice is similar to that 
observed in HIV-1 infected individuals. For instance, reactive astrocytosis that is considered 
to be the prominent feature of HIV-1 induced pathology is seen in the brain of Tat transgenic 
mice (Vitkovic and da Cunha 1995, Kim, Liu et al. 2003). Also, dendritic pathology, a 
prominent feature associated with neurocognitive impairment in HIV-1 infected individuals is 
seen in Tat expressing transgenic mice (Hagen, Haram et al. 1991, Masliah, Heaton et al. 
1997). Consistent with these findings, Tat alone has been shown to impair learning and 
memory (Carey, Sypek et al. 2012, Fitting, Ignatowska-Jankowska et al. 2013). 
Methamphetamine is the second most commonly abused illicit drug word wide. It 
poses a great risk for HIV-1 infection due to risky sexual behaviors, particularly among 
bisexual and gay men (Garofalo, Mustanski et al. 2007). It is mainly abused for its euphoric 
potential and stimulant properties on central and peripheral nervous systems. 
Methamphetamine mainly affects the dopaminergic system and also GABAergic, serotonergic 
systems in different brain regions (Ricaurte, Schuster et al. 1980, Wilson, Kalasinsky et al. 
1996). Methamphetamine abuse results in the neurotoxic effects on different regions of the 
brain, including frontal cortex, hippocampus, basal ganglia that are associated with memory, 
locomotion, cognition and executive functions (Belcher, O'Dell et al. 2005, Chang, Ernst et al. 
2005, Berman, O'Neill et al. 2008). Consistent with these findings, methamphetamine use has 
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been shown to impair learning and memory in human population and animal models (Scott, 
Woods et al. 2007, Siegel, Craytor et al. 2010, Kesby, Markou et al. 2015). The effects of 
methamphetamine on memory impairment are long lasting as measured by the decrease in 
prospective memory after 6 months of abstinence (Rendell, Mazur et al. 2009). Moreover, 
astrocytosis and dendritic pathology that are seen in HIV-1 infection are also associated with 
methamphetamine abuse (Kuczenski, Everall et al. 2007, Raineri, Gonzalez et al. 2012).  
The study was undertaken to determine the combined effects of HIV-1 Tat and 
methamphetamine on locomotion, anxiety, learning and spatial memory. Open field was used 
to measure general locomotor activity and parameters of anxiety and light/dark box was 
employed to measure anxiety. Y maze and Morris water maze were employed to evaluate the 
spatial learning and working memory in the mice. Furthermore, we also aimed to determine 
the effect of methamphetamine and HIV-1 Tat on expression of various genes associated with 
synaptic plasticity. 
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5.2 Results 
5.2.1 Effect of HIV-1 Tat and METH on ambulation  
HIV-1 infected individuals increased the prevalence of people suffering with minor 
forms of neurocognitive disorders. These HIV-1 infected individuals are associated with 
several psychiatric disorders, including distress and anxiety (Myers, Satz et al. 1997, Bing, 
Burnam et al. 2001). These influence the daily living of the people and also present a huge 
economic burden on the society. Apart from socioeconomic factors, molecular and epigenetic 
factors induced by viral proteins, especially HIV-1 Tat might play a role in mediating these 
effects. To test this hypothesis, we employed open field and light/dark box to determine 
general locomotor activity and anxiety.  
 Experiments were performed on both male and female mice to determine the gender 
differences. Doxycycline inducible HIV-1 Tat transgenic mice were used in all the experiments. 
Mice that do not express HIV-1 Tat and reverse tetracycline transactivator (rTTA) genes 
served as controls. Dose of METH was escalated from 0.1mg/kg to 6mg/kg over 1 week and 
maintained at 6mg/kg for 2 weeks before the commencement of behavioral testing. Mice were 
given equal volumes of either saline or METH twice a day through intraperitoneal injection. 
Weight of the animals were recorded every week. METH treatment regimen did not cause any 
change in the weight of the animals over the duration of the experiment (Fig. 41A, B). HIV-1 
Tat expression was determined by RT-PCR different regions of the brain (Fig. 42). Mice which 
expressed Tat and rTTA genes showed significantly high expression of HIV-1 Tat RNA 
compared to control mice. Expression was higher in cerebellum compared to prefrontal cortex 
or parietal cortex or hippocampus.  
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Figure 41: Effect of METH administration on body weight: (A, B) 6 month old wild type mice 
and HIV-1 Tat mice were administered either PBS or METH for 4 weeks. Body weight of the mice 
were taken once a week until euthanasia. METH treatment did not change body weight between 
different treatment groups in females (A) and males (B). 
Figure 42: Doxycycline formulated chow induced HIV-1 
Tat expression in different brain regions: Different brain 
regions were isolated from mice after euthanasia. Total 
RNA was isolated and 150 ng RNA was used to run RT-
PCR. Amplified product was run on 2% agarose gel and 
HIV-1 Tat was identified by presence of band at 220 bp in 
hippocampus, prefrontal cortex, parietal cortex and 
cerebellum. A representative image of Tat expression in 
one mice is shown in the figure. 
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5.2.2 Effect of HIV-1 Tat and METH in open field assay 
Generalized locomotor activity and anxiety were evaluated in control mice and HIV-1 
Tat mice that were treated with either saline or METH. Mice were placed at one of the corner 
in the apparatus and allowed to explore for 5 min. The starting position of mice was chosen 
at random. Ambulatory activity was determined by measuring the total distance traveled by 
the mice over 5 min duration. Total distance traveled by female mice was significantly higher 
compared to male mice (14.71 ± 1.3 m vs 10.75 ± 0.87 m). Chronic administration of METH 
increased the amubulatory activity in mice. The percentage increase in the total distance 
traveled compared to vehicle treated controls is 45.0 ± 18.6 % in females and 24.3 ± 20.1 % 
in males (Fig. 43A, B). Also, the total distance traveled by METH treated female mice was 
significantly higher compared to METH treated male mice (21.3 ± 2.7 m vs 13.4 ± 2.16 m) 
(p<0.01). We also calculated the distance traveled and number of entries made by the mice 
in the center zone. These two measures serve as indicators of anxiety. The distance traveled 
in center zone was significantly lower in Tat +ve mice in female (1.18 ± 0.39 vs 2.78 ± 0.57 in 
controls) and male (0.73 ± 0.22 vs 2.03 ± 0.22 in controls). Distance traveled by mice in the 
center increased in METH treated animals. The increase in the distance traveled in the center 
in METH treated HIV-1 Tat –ve mice was higher than saline administered HIV-1 Tat –ve 
controls in males and females. Similarly, distance traveled in the center was higher in METH 
treated HIV-1 Tat +ve mice compared to saline administered HV-1 Tat +ve mice in males and 
females (Fig. 43C, D). Number of entries made into the center zone was significantly lower in 
Tat +ve mice in female (7.5 ± 2.37 vs 18.17 ± 3.61 in controls) and male (6.25 ± 1.87 vs 14.64 
± 1.70 in controls). Number of entries made by mice into the center increased in METH treated 
animals. The increase in the number of entries to the center in METH treated HIV-1 Tat –ve 
mice was higher than saline administered HIV-1 Tat –ve controls in males and females. 
Similarly, number of entries made into the center was higher in METH treated HIV-1 Tat +ve 
mice compared to saline administered HV-1 Tat +ve mice in males and females (Fig. 43E, F). 
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These results indicate that HIV-1 Tat induction induced anxiety in both male and female mice. 
However, METH treatment did not exacerbate the anxiety induced by HIV-1 Tat. It further 
decreased the anxiety in HIV-1 Tat –ve mice and HIV-1 Tat +ve mice.  
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Figure 43: Effect of HIV-1 Tat and METH on ambulatory activity in open field assay: (A-F) )  6 
month old wild type mice and HIV-1 Tat mice were administered either PBS or METH for 3 weeks 
and tested on open field assay. (A,B) Total distance traveled by mice over 5 min test duration was 
measured in females (A) and males (B). (C, D) Total distance traveled by mice in the center zone 
over 5 min test duration was measured in females (C) and males (D). (E, F) Number of entries into 
center zone over 5 min test duration was measured in females (E) and males (F). * indicates p-value 
< 0.05 compared to WT controls; ^ indicates p-value < 0.1 compared to WT controls. 
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5.2.3 Effect of HIV-1 Tat and METH in Light/dark box assay 
We have employed light dark box to evaluate anxiety like phenomenon in mice after 
chronic HIV-1 Tat induction and/or METH treatment. Mice were placed into the apparatus and 
activity was monitored over a duration of 10 min. Amount of time spent and number of entries 
made into light zone were measured and served as indicators of anxiety. Chronic HIV-1 Tat 
induction decreased the time spent in light zone compared to control mice of both sexes (31.8 
± 5.35 sec vs 39.14 ± 4.85 sec in females and 20.45 ± 4.84 sec vs 52.72 ± 11.09 in males). 
(Fig. 44A, B).However, statistical significance was achieved only in male mice, but not in 
female mice. Chronic administration of METH has increased the time spent in the light zone. 
It increased from 39.14 ± 4.85 sec to 49.10 ± 6.67 sec in females and from 52.72 ± 11.09 sec 
to 67.46 ± 12.75 sec in males. Administration of METH to HIV-1 Tat +ve mice also showed 
similar phenomenon compared to saline administered HIV-1 Tat +ve mice in both the sexes. 
Results from entries made into light zone also showed similar phenomenon (Fig. 44C, D). 
Thus, the results from open field and light dark box assays indicate that chronic HIV-1 Tat 
induction results in anxiety like phenomenon and this is over come in mice that were 
administered METH.  
  
109 
 
  
Figure 44: Effect of HIV-1 Tat and METH on anxiety in Light/dark box assay: (A-D) 6 month old 
wild type mice and HIV-1 Tat mice were administered either PBS or METH for 3 weeks and tested 
on Light/dark box assay. (A, B) Time spent by mice in light zone over 10 min test duration was 
measured in females (A) and males (B). (C, D) Entries made into light zone over 10 min test duration 
was measured in females (C) and males (D). * indicates p-value < 0.05 compared to WT controls. 
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5.2.4 Effect of HIV-1 Tat and METH on working memory 
HIV-1 seropositive individuals who abuse drugs are associated with increased working 
memory deficits compared to HIV-1 seronegative drug users (Bartok, Martin et al. 1997). Also, 
HIV-1 infection alone is associated with decline in working memory (Stout, Salmon et al. 1995, 
Hinkin, Hardy et al. 2002). Furthermore, long term METH administration lead to deficits in 
memory (Recinto, Samant et al. 2012). However, the combined effect of HIV-1 Tat and METH 
is unknown. In order to determine the combined effect of HIV-1 Tat and METH on 
neurocognition, we have employed Y-maze and Morris water maze. Experiments were 
performed on both male and female mice to determine the sex differences. Doxycycline 
inducible HIV-1 Tat transgenic mice were used in all the experiments. Mice that do not express 
HIV-1 Tat and rTTA genes served as controls. Dose of METH was escalated from 0.1mg/kg 
to 6mg/kg over 1 week and maintained at 6mg/kg for 2 weeks before the commencement of 
behavioral testing. Mice were given equal volumes of either saline or METH twice a day 
through intraperitoneal injection.  
Spontaneous alternation was evaluated using Y-maze and serves as an indicator of 
working memory.  A significant decrease in the spontaneous alternation was observed in HIV-
1 Tat mice administered METH in both male and female mice compared to vehicle treated 
control group (n=8-13 per group; p<0.05; Fig. 45A, B).). Despite the trend, HIV-1 Tat induction 
alone did not affect spontaneous alteration compared to the control group in both the sexes 
(p>0.05). However, there was a significant decrease in the spontaneous alteration of 
methamphetamine treated male mice compared to the control group (p=0.09), but not the 
female mice. Compared to HIV-1 Tat male group, there was significant decrease in 
spontaneous alternation in HIV-1 Tat mice treated with METH (p<0.05). There was no 
difference in any of the groups based on the gender. Furthermore, there were no significant 
differences in the number of total arm entries made by mice in each group in both the sexes 
(Fig. 45C, D). Also, the number of arm entries between the sexes remained similar across 
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different groups. This indicates that general locomotor function was not altered and did not 
influence the effects of HIV-1 Tat and METH alone or in combination on spontaneous 
alternation.  
 
 
  
Figure 45: Effect of HIV-1 Tat and METH on spontaneous alternations in Y-maze: (A, B) 6 
month old wild type mice and HIV-1 Tat mice were administered either PBS or METH for 3 weeks 
and tested on Y maze for 5 min. HIV-1 Tat positive mice that were administered METH showed 
significantly lower number of spontaneous alternations compared to WT mice in females (A) and 
males (B) (p<0.05, one-way ANOVA with Tukey’s post hoc analysis). (C, D) The total number of 
arm entries made by mice were not significantly different between different treatment groups in 
females (C) and males (D). * indicates p-value < 0.05 compared to WT controls; ^ indicates p-value 
< 0.1 compared to WT controls; # denotes p-value < 0.05 compared to HIV-1 Tat mice.  
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5.2.5 Effect of HIV-1 Tat and methamphetamine on spatial learning and memory 
Morris water maze is commonly employed to demonstrate deficits in spatial learning 
and memory in rodents. Previous studies have indicated decline in spatial learning and 
memory with HIV-1 Tat or METH alone (Camarasa, Rodrigo et al. 2010, Carey, Sypek et al. 
2012, Chen, Liu et al. 2012, Fitting, Ignatowska-Jankowska et al. 2013).  Therefore, we 
determined the combined effect of HIV-1 Tat and METH on spatial learning and memory using 
Morris water maze. Spatial learning was evaluated by determining the time taken to reach the 
escape platform over 5 days of acquisition trial, and reference memory was evaluated by 
determining time spent in target quadrant and number of annulus entries (platform crossings) 
in probe trial. Data was normally distributed in all the groups between sexes (Shapiro Wilk 
test; p>0.05 for all groups). Mice in control group from both sexes learnt to find the escape 
platform quickly compared to the other groups. Escape latency was 38.2 ± 3.6 sec on D1 
compared to 14.6 ± 1.9 sec on D5 for male mice and 39.2 ± 3.1 sec on D1 compared to 13.1 
± 1.4 sec on D5 for female mice (Fig. 46A, B). Induction of HIV-1 Tat resulted in longer times 
to find the escape platform in male and female mice (p=0.059 for males and p<0.01 for 
females). METH treatment resulted in longer times to find the escape platform, but reached 
statistical significance only in females (p<0.01). However, HIV-1 Tat mice that are treated with 
METH took significantly longer time to reach the hidden platform compared to other treatment 
groups in both the sexes (p<0.01). We also determined the swim speed of the animals over 
the course of acquisition trial (Fig. 46C, D). Average swim speed of the animals between 
different groups remained consistent over the duration of acquisition trial, indicating that 
treatment did not affect the swim speed of the animals. No significant differences were 
observed in the swim speeds of the animals between the sexes.  
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Figure 46: METH treated HIV-1 Tat mice showed impaired spatial learning in Morris water maze: 
(A, B)  6 month old wild type mice and HIV-1 Tat mice were administered either PBS or METH for 3 
weeks and tested on Morris water maze. Escape latency (sec) was measured over of five day 
acquisition trial. Values represented are mean ± SE of all trials in all the mice of a particular group. 
There was significant increase in the escape latency of HIV-Tat female mice (p<0.01) and male mice 
(p=0.059), METH treated female mice (p<0.01) and METH treated HIV-1 Tat female mice (p<0.01) 
and male mice (P<0.01). (C, D) Swimming speed was calculated over five day acquisition trial and no 
significant difference was observed between different groups in females (C) and males (D).  
114 
 
A probe trial was conducted 24 h after the acquisition trial to evaluate reference 
memory. Animals from control group from both the sexes memorized the platform location 
better than animals from other groups, indicted by the time spent in the target quadrant (22.18 
± 1.58 sec for females vs 20.09 ± 1.24 sec for males) (Fig. 47A, B). There was a significant 
decrease in the time spent by the animals in the target quadrant from HIV-1 Tat group and 
combination group (HIV-1 Tat + METH) in both males and females (p<0.05). Time spent by 
the animals in the target quadrant was significantly less in the combination group compared 
to only METH treated group in males, but not in females (Fig. 41A, B). Furthermore, data from 
the number of platform crossings showed similar results that align with the time spent in target 
quadrant (Fig. 47C, D). There was no difference in the number of platform crossings between 
similar groups in males and females. These results indicate that reference memory was 
affected by HIV-1 Tat and METH did not worsen it. 
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Figure 47: METH treated HIV-1 Tat mice showed impaired spatial learning and memory in Morris 
water maze: (A, B)  6 month old wild type mice and HIV-1 Tat mice were administered either PBS or 
METH for 3 weeks and tested on Morris water maze. Each mice was given 60 sec probe trial and time 
spent in target quadrant (A, B) and total number of annulus entries (platform crossings) (C, D) were 
calculated. Time spent in target quadrant were significantly lower in HIV-1 Tat mice and HIV-1 Tat 
mice that were administered METH in females (A) and males (B) compared to WT controls. Total 
number of annulus entries were decreased in HIV-1 Tat mice and HIV-1 Tat mice that were 
administered METH in females (C) and males (D) compared to WT controls. There was no statistical 
difference between sexes (female vs. male) as calculated through ANOVA.  * indicates p-value < 0.05 
compared to WT controls; # denotes p-value < 0.05 compared to HIV-1 Tat mice; ! denotes p-value 
<0.05 compared METH administered mice.  
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5.2.6 Effect of HIV-1 Tat and METH on expression of synaptic proteins 
We wanted to determine the mechanisms that are associated with deficits in learning 
and memory with HIV-1 Tat and METH. Mice were humanely euthanized and brain to body 
ratio was calculated (Fig. 48A, B). There was no significant difference in the brain weights 
between different treatment groups in both sexes. 
 
 
 
 
 
 
 
Figure 48: Effect of HIV-1 Tat and METH on brain to body weight ratio: (A, B) 6 month old wild 
type mice and HIV-1 Tat mice were administered either PBS or METH for 4 weeks. Brain weight and 
body weight of the mice were taken at euthanasia. HIV-1 Tat induction and METH treatment did not 
affect brain weight to body weight ratio between different treatment groups in females (A) and males 
(B). 
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Milder forms of neurocognitive impairments mediated by HIV-1 result in changes to 
synapse organization without neuronal death (Everall, Heaton et al. 1999). Therefore, we 
sought to determine the expression of various synaptic proteins in response to HIV-1 Tat 
and METH. Synaptic proteins are involved in transmission of synapse and also serve as 
scaffolds. They are involved in the consolidation of short term memory events into long term 
memory events (Schmitt, Tanimoto et al. 2009). There are different types of synaptic 
proteins with diverse functions, classified into pre-synaptic and post-synaptic proteins. 
Therefore, we performed western blot to determine the effect of HIV-1 Tat and METH on 
expression of various synaptic proteins, including two pre-synaptic proteins (synapsin1, 
synaptophysin) and three post-synaptic proteins (PSD-95, Arg3.1 and shank).  
5.2.1.1 Effect of HIV-1 Tat and METH on synaptophysin 
In order to determine the effect of HIV-1 Tat and METH on synaptic plasticity, we 
examined the expression of synapsin1 and synaptophysin, two important pre-synaptic 
proteins in different regions of the brain. Synaptophysin, important pre-synaptic protein plays 
an important role in formation of synapse and vesicle endocytosis. Similar to synapsin1, HIV-
1 Tat and METH decreased its expression in parietal cortex. Compared to the individual 
groups, expression of synaptophysin was significantly affected in HIV-1 Tat mice treated with 
METH, with a decrease of 41 ± 4.5% in males and 40 ± 5.6% in females (Fig. 49A, B). 
Synaptophysin expression was also decreased in the hippocampus of HIV-1 Tat induced male 
mice (with or without METH), but not in the METH alone treated mice. Furthermore, 
synaptophysin expression remained unchanged in female hippocampus and other brain 
regions of both male and female mice.  
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Figure 49: Effect of HIV-1 Tat and METH on the expression of pre-synaptic proteins: (A-B) 
WT control mice and HIV-1 Tat mice were treated with either PBS or METH. Different brain regions 
were isolated as described in materials and methods. Similar protein concentration from all the mice 
in a group were pooled together (n=8-13). (A, B) Expression of synaptophysin was measured in 
different brain regions through western blot in females (A) and males (B). Results are expressed as 
mean ± SE of at least 3 different western blots. Single GAPDH was used as a representative loading 
control. One-way AVOVA with Tukey’s post hoc for multiple comparisons was performed to 
calculate the statistical significance. * indicates p-value < 0.05 compared to WT controls. 
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5.2.1.2 Effect of HIV-1 Tat and METH on synapsin1 
Synapsin1 accounts for the abundant pre-synaptic protein present in the synaptic 
vesicles of nerve terminals. It facilitates the release of neurotransmitters that aid in long term 
potentiation and memory formation. Expression of synapsin1 was decreased in response to 
HIV-1 Tat induction in parietal cortex of both males and females by 21 ± 6.3% and 24 ± 1.8%, 
respectively (Fig. 50A, B). Similar to HIV-1 Tat, METH treatment decreased the expression of 
synapsin1 in parietal cortex, which was 37 ± 4.3% and 18 ± 4.7% in males and females, 
respectively (Fig. 50A, B). Syanpsin1 was also decreased in HIV-1 Tat mice treated with 
METH in both genders. METH treated female mice showed a significant reduction in the 
expression of synapsin1 in hippocampus. (Fig 50A). No significant change in the expression 
of synapsin1 was observed in other brain regions. Furthermore, the expression of synapsin1 
was increased in the cerebellum of HIV-1 Tat mice that were given methamphetamine.  
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Figure 50: Effect of HIV-1 Tat and METH on the expression of synapsin1: (A-B) WT control 
mice and HIV-1 Tat mice were treated with either PBS or METH. Different brain regions were 
isolated as described in materials and methods. Similar protein concentration from all the mice in 
a group were pooled together (n=8-13). (A, B) Expression of synapsin1 was measured in different 
brain regions through western blot in females (A) and males (B). Results are expressed as mean 
± SE of at least 3 different western blots. Single GAPDH was used as a representative loading 
control. One-way AVOVA with Tukey’s post hoc for multiple comparisons was performed to 
calculate the statistical significance. * indicates p-value < 0.05 compared to WT controls. 
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5.2.7 Effect of HIV-1 Tat and METH on post-synaptic proteins 
5.2.7.1 Effect of HIV-1 Tat and METH on PSD-95 
Post synaptic density protein 95 (PSD-95) belongs to the family of membrane 
associated guanylate kinase. It is one of the most important post-synaptic proteins that is 
involved in synaptic transmission and associated with various forms of memory. It promotes 
bidirectional synaptic plasticity by interacting with NDMA and AMPA receptors (Beique and 
Andrade 2003). Previous studies have indicated the key role of PSD-95 in spatial learning, 
associative learning and fear memory (Migaud, Charlesworth et al. 1998, Nithianantharajah, 
Komiyama et al. 2013, Rashid, Cole et al. 2014, Fitzgerald, Pinard et al. 2015). Recent studies 
have indicated the role of HIV-1 and HIV-1 Tat on the expression of PSD-95 on human 
neuroblastoma and isolated rat hippocampal neurons, respectively (Atluri, Kanthikeel et al. 
2013, Hargus and Thayer 2013). Therefore, we determined the expression levels of PSD-95 
in response to methamphetamine treatment and/or HIV-1 Tat induction. PSD-95 expression 
was determined by immunoblot on different brain regions of male and female mice. HIV-1 Tat 
induction decreased the expression of PSD-95 in prefrontal cortex by 20 ± 3.0% and METH 
treatment decreased PSD-95 expression by 21 ± 4.2% in parietal cortex of male mice (Fig. 
51B). PSD-95 expression was not altered by HIV-1 Tat induction or treatment with METH in 
different brain regions of both male and female mice (Fig. 51A, B). However, expression of 
PSD-95 was significantly decreased in HIV-1 Tat and METH group of male and female mice 
in different brain regions, including hippocampus, prefrontal cortex and parietal cortex. 
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Figure 51: Effect of HIV-1 Tat and METH on the expression of PSD95: (A-B) WT control mice 
and HIV-1 Tat mice were treated with either PBS or METH. Different brain regions were isolated as 
described in materials and methods. Similar protein concentration from all the mice in a group were 
pooled together (n=8-13). (A, B) Expression of PSD95 was measured in different brain regions 
through western blot in females (A) and males (B). Results are expressed as mean ± SE of at least 
3 different western blots. Single GAPDH was used as a representative loading control. One-way 
AVOVA with Tukey’s post hoc for multiple comparisons was performed to calculate the statistical 
significance. * indicates p-value < 0.05 compared to WT controls; # denotes p-value < 0.05 compared 
to HIV-1 Tat mice; ! denotes p-value <0.05 compared METH administered mice. 
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5.2.7.2 Effect of HIV-1 Tat and METH on ARG3.1 
Activity regulated cytoskeleton-associated protein (Arg3.1) is an important immediate 
early gene that is involved in various memory processes, including formation of spatial 
memory and fear memory (Guzowski, Lyford et al. 2000, Monti, Berteotti et al. 2006). 
Activated syanpses and dendrites contain newly transcribed arg3.1 and this modulates the 
expression of AMPA receptors (Rial Verde, Lee-Osbourne et al. 2006). HIV-1 Tat induction 
and METH treatment alone decreased the expression of arg3.1 in parietal cortex of both male 
and female mice (Fig. 52A, B). However, arg3.1 expression was significantly reduced in HIV-
1 Tat mice treated with METH. The decrease in arg3.1 expression was significant in parietal 
cortex (31 ± 8.3% in males and 41 ± 6.0% in females) and prefrontal cortex (22 ± 1.6% in 
males and 32 ± 1.8% in females) (Fig. 52A, B). 
  
124 
 
  
Figure 52: Effect of HIV-1 Tat and METH on the expression of ARG3.1: (A-B) WT control mice 
and HIV-1 Tat mice were treated with either PBS or METH. Different brain regions were isolated 
as described in materials and methods. Similar protein concentration from all the mice in a group 
were pooled together (n=8-13). (A, B) Expression of ARG3.1 was measured in different brain 
regions through western blot in females (A) and males (B). Results are expressed as mean ± SE 
of at least 3 different western blots. Single GAPDH was used as a representative loading control. 
One-way AVOVA with Tukey’s post hoc for multiple comparisons was performed to calculate the 
statistical significance. * indicates p-value < 0.05 compared to WT controls; # denotes p-value < 
0.05 compared to HIV-1 Tat mice; ! denotes p-value <0.05 compared METH administered mice. 
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5.2.7.3 Effect of HIV-1 Tat and METH on Shank2 
Shank2 is a post-synaptic protein that plays vital role in synaptogenesis. It contains 
multiple protein binding domains that facilitates the association of different molecules. We 
evaluated the expression of shank2 in different brain regions by western blot analysis. 
Expression of shank was significantly altered in the prefrontal cortex region of male and 
female HIV-1 Tat mice treated with METH (28 ± 2.7% in males and 18 ± 0.9% in females). 
The decrease in shank 2 expression of HIV-1 Tat mice or methamphetamine treated mice 
was less than the combination group. Expression of shank2 remained unchanged in other 
brain regions. However, its expression significantly increased in the cerebellum in the 
treatment groups of both male and female (Fig. 53A, B). 
These results indicate that HIV-1 Tat and METH combination significantly affected the 
expression of many pre-synaptic and post-synaptic proteins that are responsible for proper 
synaptic transmission and function. 
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Figure 53: Effect of HIV-1 Tat and METH on the expression of SHANK2: (A-B) WT control mice 
and HIV-1 Tat mice were treated with either PBS or METH. Different brain regions were isolated as 
described in materials and methods. Similar protein concentration from all the mice in a group were 
pooled together (n=8-13). (A, B) Expression of SHANK2 was measured in different brain regions 
through western blot in females (A) and males (B). Results are expressed as mean ± SE of at least 
3 different western blots. Single GAPDH was used as a representative loading control. One-way 
AVOVA with Tukey’s post hoc for multiple comparisons was performed to calculate the statistical 
significance. * indicates p-value < 0.05 compared to WT controls; # denotes p-value < 0.05 compared 
to HIV-1 Tat mice;  
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5.2.8 Effect of HIV-1 Tat and methamphetamine on expression of neurotropic factors 
Neurotrophic factors perform important roles in synaptic plasticity, neuronal 
development, survival and proper function (Huang and Reichardt 2001, Sofroniew, Howe et 
al. 2001, Bramham and Messaoudi 2005). Neurotrophins exert their function by the activation 
of different classes of receptors, including receptor tyrosine kinases and TNF receptor 
superfamily. Decrease in the expression of various neurotrophins is associated with various 
disease states, including Alzheimer’s disease (Connor, Young et al. 1997), Parkinson’s 
disease (Nagatsu and Sawada 2007) and HIV infected individuals with encephalitis (Fields, 
Dumaop et al. 2014). Owing to their role in long term potentiation and memory, neurotrophins 
are being developed as therapeutic agents. Previous studies have indicated the role of HIV-1 
Tat and METH on expression of different neurotrophic factors (Angelucci, Gruber et al. 2007, 
Darbinian, Darbinyan et al. 2008). In order to determine the combined effect of HIV-1 Tat and 
METH on the expression of various neurotrophic factors, we performed western blot on 
different brain regions. We determined the expression of brain-derived neurotrophic factor 
(BDNF) and ciliary neurotrophic factor (CNTF) in prefrontal cortex, parietal cortex, 
hippocampus and cerebellum. Expression of BDNF was upregulated in prefrontal cortex and 
cerebellum of female Tat mice, but not male Tat mice (Fig. 54A, B). However, expression of 
BDNF remained unchanged in hippocampus and parietal cortex of male and female Tat mice. 
METH treatment resulted in significant decrease in the expression of BDNF in parietal cortex, 
hippocampus and prefrontal cortex of female mice and prefrontal cortex and cerebellum of 
male mice. HIV-1 Tat mice treated with METH showed significant decrease in the expression 
of BDNF in all the brain regions of both male and female mice. Expression of BDNF was 
significantly lower in the combination group compared to either HIV-1 Tat or MA groups. We 
also determined the expression of CNTF in different brain regions of both male and female 
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mice (Fig. 55A, B). However, no significant differences were observed in any of the treatment 
groups in both the genders. 
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Figure 54: Effect of HIV-1 Tat and METH on the expression of BDNF: (A-B) WT control mice and 
HIV-1 Tat mice were treated with either PBS or METH. Different brain regions were isolated as 
described in materials and methods. Similar protein concentration from all the mice in a group were 
pooled together (n=8-13). (A, B) Expression of BDNF was measured in different brain regions through 
western blot in females (A) and males (B). Results are expressed as mean ± SE of at least 3 different 
western blots. Single GAPDH was used as a representative loading control. One-way AVOVA with 
Tukey’s post hoc for multiple comparisons was performed to calculate the statistical significance. * 
indicates p-value < 0.05 compared to WT controls; # denotes p-value < 0.05 compared to HIV-1 Tat 
mice;  
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Figure 55: Effect of HIV-1 Tat and METH on the expression of CNTF: (A-B) WT control mice and 
HIV-1 Tat mice were treated with either PBS or METH. Different brain regions were isolated as 
described in materials and methods. Similar protein concentration from all the mice in a group were 
pooled together (n=8-13). (A, B) Expression of CNTF was measured in different brain regions through 
western blot in females (A) and males (B). Results are expressed as mean ± SE of at least 3 different 
western blots. Single GAPDH was used as a representative loading control. One-way AVOVA with 
Tukey’s post hoc for multiple comparisons was performed to calculate the statistical significance.  
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5.2.9 Effect of HIV-1 Tat and methamphetamine on p-CaMKII expression 
CaMKII is highly expressed protein in the brain and is present in abundant quantities 
in post synaptic density. Activation of CaMKII results in the induction of long term potentiation 
by its effects on AMPA receptors (Sanhueza and Lisman 2013). Therefore, we measured the 
effect of HIV-1 Tat and METH on the expression of CaMKII by western blot. We specifically 
measured the phosphorylated form of CamKII on threonine 286, an active form. As shown in 
figure Fig 50A and 50B, HIV-1 Tat has significantly decreased the expression of p-CaMKII in 
parietal cortex, prefrontal cortex and cerebellum of HIV-1 Tat induced male mice, but not 
female mice (Fig 56B). Furthermore, METH treatment caused a significant decrease in the 
expression of p-CaMKII in all the brain regions, including hippocampus, prefrontal cortex, 
parietal cortex and cerebellum. Furthermore, administration of METH to HIV-1 Tat mice 
showed a significant decrease in all the brain regions of both male and female compared to 
HIV-1 Tat or METH alone (Fig. 56A, B).  
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Figure 56: Effect of HIV-1 Tat and METH on the expression of p-CaMKII: (A-D) WT control mice 
and HIV-1 Tat mice were treated with either PBS or METH. Different brain regions were isolated as 
described in materials and methods. Similar protein concentration from all the mice in a group were 
pooled together (n=8-13). (A, B) Expression of p-CaMKII was measured in different brain regions 
through western blot in females (A) and males (B). Results are expressed as mean ± SE of at least 
3 different western blots. Single GAPDH was used as a representative loading control. One-way 
AVOVA with Tukey’s post hoc for multiple comparisons was performed to calculate the statistical 
significance. * indicates p-value < 0.05 compared to WT controls; # denotes p-value < 0.05 compared 
to HIV-1 Tat mice; ! denotes p-value <0.05 compared METH administered mice. 
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5.3 Discussion 
METH dependence increases the risk for HIV-1 infection and also in the development 
of associated neuropsychological impairments (Rippeth, Heaton et al. 2004). There is 
significant decrease in the number of interneurons in the frontal cortex of HIV-1 infected 
individuals with a history of METH use (Chana, Everall et al. 2006). HIV-1 viral proteins, 
including HIV-1 Tat and gp120 are known to play an important role in the development of 
psychological and neurological impairments that are similar to those seen in HIV-1 infected 
individuals (Carey, Sypek et al. 2012, Hoefer, Sanchez et al. 2015, Kesby, Markou et al. 2015, 
Marks, Paris et al. 2016). In the present study, we wanted to determine the effect of escalating, 
multiple dose METH regimen in adult HIV-1 Tat transgenic mice that conditionally express 
HIV-1 Tat in the presence of doxycycline. As previously reported, multiple and escalating 
doses of METH did not induce hyperthermia (data not shown) and reflected abuse pattern 
seen in human population (Furtmuller, Arnhold et al. 2003, Hoefer, Sanchez et al. 2015). 
Previous studies by different groups have indicated that HIV-1 Tat induces anxiety. Our results 
from open field assay and light/dark box are in agreement with those results. However, there 
were no adverse effects of METH administration in control and Tat transgenic mice. 
Furthermore, the present treatment has decreased the anxiety levels induced by HIV-1 Tat. 
Future studies are required to determine the long term effects of HIV-1 Tat and METH on 
anxiety. 
Previous studies using escalating and multiple doses of METH in mice have shown 
increased latency to escape in Barnes maze and alterations in the prepulse inhibition (Henry, 
Geyer et al. 2014). Our Y maze results indicated that there is significant difference in the 
working memory as indicated by the number of spontaneous alternations made in HIV-1 Tat 
transgenic mice that were treated with METH. Chronic HIV-1 Tat induction did not affect the 
number of spontaneous alterations compared to control in both male and female. Treatment 
with METH showed a trend towards decreased number of spontaneous alterations. There was 
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no difference in the number of spontaneous alterations based on the gender. Results from 
morris water maze indicated that both HIV-1 Tat and METH affected spatial learning. 
However, combination of HIV-1 Tat induction and METH treatment resulted in longest times 
to reach the escape platform during the acquisition trial. There was no significant effect of 
METH on the time spent in target quadrant and number of platform crossings in probe trial, in 
both wild type and HIV-1 Tat transgenic mice. These results indicate that METH treatment did 
not affect the reference memory. Results from Y maze and morris water maze indicate that 
executive function is more compromised in the combination mice group (HIV-1 Tat and 
METH). This is in agreement with the previous studies indicating poor working memory in 
METH users and HIV-seropositive individuals (Stout, Salmon et al. 1995, Gonzalez, Bechara 
et al. 2007). 
Proper synaptic integrity is required for transmission of information and thereby 
achieving synaptic plasticity. There are different number of synaptic proteins, located either 
presynaptically or postsynaptically that are responsible for the maintenance of synaptic 
integrity. We evaluated the expression of synaptophysin and synapsin I as markers of pre-
synaptic integrity. PSD-95, Arc and Shank 2 are evaluated as markers of post-synaptic 
integrity. Synaptophysin is a protein located abundantly in the synaptic vesicle with diverse 
functions, including regulation of synaptic vesicle endocytosis, synapse formation and long 
term potentiation (Goodglick and Kane 1990, Janz, Sudhof et al. 1999, Tarsa and Goda 2002). 
Protein expression analysis indicates that the levels of synaptophysin were affected by HIV-1 
Tat and METH in parietal cortex of both males and females. The effect was more pronounced 
in HIV-1 Tat mice treated with methamphetamine. The results are consistent with previous 
reports indicating decreased synpatophysin expression in cell culture and animal models of 
HIV and METH induced brain injury (Kaewsuk, Sae-ung et al. 2009, Maung, Hoefer et al. 
2014, Torres and Noel 2014).  
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Synapsin is a pre-synaptic protein that is present in the synaptic vesicles of nerve 
terminals. It facilitates the organization of synaptic vesicle clusters and modulates the release 
of neurotransmitters (Bykhovskaia 2011). HIV-1 infection reduced the expression of synapsin 
1 in the synaptosomes and the degree of reduction correlated with the viral load (Gelman and 
Nguyen 2010). Also, chronic METH administration decreased the expression of synapsin 1 in 
rats (Wang, Sun et al. 2012). Similar to these findings, our results indicated reduced 
expression of synapsin 1 in various brain regions of HIV-1 Tat induced animals and animals 
treated with chronic METH regimen. Decreased expression of synpasin 1 might result in the 
depletion of synaptic vesicles in the releasable pool and thereby affects synaptic plasticity 
(Gitler, Takagishi et al. 2004). Future studies are required to determine the effect of HIV-1 Tat 
and METH on reduced expression of synapsin 1 at excitatory synapses or inhibitory synapses. 
Owing to its role in CNS development and function, we have also determined the 
expression of PSD-95 as a marker for post-synaptic plasticity. PSD95 expression was 
unaltered in most brain regions upon HIV-1 Tat induction or treatment with METH. Significant 
difference in the expression of PSD-95 was observed in the combination group of both the 
genders in different brain regions. Decrease in the expression of PSD-95 decreases the ability 
of glutamate receptors to connect with the intracellular signaling pathways (Sheng 2001). This 
could be partly responsible for decreased long term potentiation that was previously observed 
in mice expressing HIV-1 Tat protein or treated with amphetamines (Xu, Ma et al. 2010, Fitting, 
Ignatowska-Jankowska et al. 2013).  
Arc is an important post-synaptic protein that is involved in learning and memory (Czerniawski, 
Ree et al. 2011). Increased expression of Arc is associated with activity of neurons 
responsible for storing and processing information (Guzowski, McNaughton et al. 1999). 
Furthermore, Arc knockout mice have been shown to perform poorly in water maze task 
(Plath, Ohana et al. 2006). Determination of Arc by western blotting indicated that HIV-1 Tat 
and METH have significantly decreased its expression in the parietal cortex of both genders, 
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but not in the other brain regions. There was further decrease in the expression of Arc in HIV-
1 Tat mice treated with METH in parietal cortex and prefrontal cortex. Our findings concur 
previous reports, indicating decreased expression of Arc in different brain regions of mice after 
treatment with METH (Bowyer, Pogge et al. 2007, Cheng, Hsu et al. 2015). Atluri et al. 
reported a decrease in the expression of Arc in the HIV-1 infected human astrocytes (Atluri, 
Kanthikeel et al. 2013). The expression of Shank 2 was affected by METH administration and 
HIV-1 Tat induction in different brain regions of male and female mice.  
Different types of neurotrophic factors exist in the brain with diverse functions on 
neuronal plasticity, survival and development (Huang and Reichardt 2001). Altered 
expression of neurotrophic factors are associated with neurological disorders, including HIV-
1 (Albrecht, Garcia et al. 2006, Fields, Dumaop et al. 2014). Results of western blot analysis 
indicated that HIV-1 Tat does not affect the levels of BDNF whereas METH significantly 
decreased the expression of BDNF in different brain regions. However, previous studies have 
showed that METH induces the expression of BDNF in multiple brain regions in rat (Galinato, 
Orio et al. 2015, Garcia-Cabrerizo and Garcia-Fuster 2016). A plausible explanation for this 
could be a shorter duration of METH administration (Braun, Herring et al. 2011) or METH 
administered to postnatal mice (Grace, Schaefer et al. 2008), as opposed to the long-term 
METH treatment protocol that we have employed. The increase in the levels of BDNF can be 
a compensatory mechanism to overcome the neurotoxic effects of METH. A significant 
decrease in the expression of BDNF with METH treatment and HIV-1 Tat induction could be 
responsible for increased spatial memory deficits in these mice. Therefore, administration of 
BDNF can be used as a therapeutic approach to counteract the memory deficits associated 
with HIV-1 and METH. There were no significant differences in the expression of CNTF in any 
of the brain regions of both genders.  
Previous studies have indicated the vital role of CaMKII to promote memory formation 
by strengthening the synapse. It is involved in the process of long term potentiation by 
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modulating the expression and conductance of AMPA and glutamate receptors (Benke, Luthi 
et al. 1998, Lisman, Schulman et al. 2002). Activation of enzyme catalytic site occurs through 
phosphorylation of Threonine 286 (Yang and Schulman 1999). We, therefore, examined the 
expression of CaMKII as a marker of synaptic plasticity and strength. The expression of p-
CaMKII was found to be significantly lower in HIV-1 Tat induced mice and mice treated with 
METH. Previous studies performed on primary rat cortical neurons and in SIV infected 
monkeys have shown a decrease in the expression levels of p-CaMKII (Gupta, Kelly et al. 
2010, Akay, Cooper et al. 2014). Furthermore, acute and chronic METH administration have 
been shown to affect the expression of CaMKII in rat (Akiyama and Suemaru 2000). The 
decrease in the expression levels of CamKII might affect the function of synapsin 1 and 
thereby affecting the vesicle number in the releasable pool (Greengard, Valtorta et al. 1993).  
In conclusion, administration of METH to HIV-1 Tat transgenic mice exacerbated the 
deficits in spatial learning and memory characterized by decreased spontaneous alternations 
in Y maze and increased latency time to reach the escape platform in Morris water maze. We 
correlated the changes in learning by measuring various synaptic markers and neurotropic 
factors that contribute to neuroplasticity and memory formation. HIV-1 Tat transgenic mice 
that were treated with METH showed significant decrease in the expression of synaptic 
markers and neurotropic factors. Future studies will be directed to identify the molecular 
mechanisms that are involved in the altered expression of synaptic markers and neurotropic 
factors by HIV-1 Tat and METH. Furthermore, future studies will also focus on the 
inflammation markers, structural changes of neurons and use of therapeutic agent to 
overcome the cognitive deficits mediated by HIV-1 Tat and METH. 
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CHAPTER 6 
SUMMARY AND FUTURE DIRECTIONS 
The incidence of HIV associated neurocognitive disorders have decreased over the 
past 2 decades with the initiation of cART. However, the prevalence of less severe forms 
neurocognitive disorders have increased at the same time. This presents a difficulty in 
performing day to day activities among HIV infected individuals and also a huge economic 
burden on the society. Since, HIV cannot infect neurons, neurotoxicity mediated by HIV-1 
could be a result of direct infection of astrocytes and microglia or release of soluble mediators 
that in turn acts on cells of CNS origin to produce toxicity. Among the released soluble 
mediators is HIV-1 Tat that plays an important role in promoting neurotoxicity. This 
neurotoxicity is further exacerbated in individuals who abuse illicit drugs.  
The present study was undertaken to determine the role of HIV-1 in the production of 
pro-inflammatory cytokines from astrocytes. HIV-1 Tat mediated time dependent increase in 
the expression of IL-6, IL-8 and CCL5 at the level of mRNA and protein. Upregulation of these 
cytokines involved different upstream signaling molecules and transcription factors. These 
upstream signaling molecules include PI3K/Akt and MAPKs such as p38 and JNK. These 
cytokines involve the activation of NF-κB and AP-1 transcription factors. The involvement of 
various signaling molecules were verified by the use of specific inhibitors and siRNA. We have 
also shown that HIV-1 Tat mediated induction of IL-6 is exacerbated by methamphetamine 
administration and involves overlapping NF-κB and PI3K/Akt signaling pathways. 
We also undertook an in vivo study to determine the effect of HIV-1 Tat and METH on 
various behavior paradigms. Effect of HIV-1 Tat and METH on ambulation and anxiety were 
determined by employing open field assay and light/dark box assay. Furthermore, the 
combined effect of HIV-1 Tat and METH on neurocognition was correlated to changes in the 
expression levels of various synaptic proteins, neurotrophic factors and secondary calcium 
messenger.  
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6.1 Conclusions and future directions 
This study provides novel evidence to elucidate the extensive involvement of pro-
inflammatory cytokines, and role of synaptic proteins and neurotrophic factors in exposure to 
METH and HIV-1 Tat. Following future investigations are required to further explain the role 
of HIV-1 Tat and METH. 
1. The intersection between the molecular events evoked by METH and HIV-1 Tat and 
their functional outcomes, such as expression of ER stress and oxidative stress, 
are required for comprehensive understanding of their role. 
2.  Future studies are required to understand the effects of HIV-1 Tat and METH on 
inflammation markers, synaptic changes in neurons and use of therapeutic agent 
to overcome the cognitive deficits mediated by HIV-1 Tat and METH. 
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